NFOG 2008
XXXVI Congress of the Nordic Federation of Societies of Obstetrics and Gynecology

June 14th–17th 2008, Reykjavik Iceland

PROGRAMME AND ABSTRACTS

www.nfog2008.is
Dear colleagues, welcome to Reykjavík!

The 36th NFOG congress has commenced and many people deserve thanks for making this possible. Our federation, NFOG, plays an important role in bringing us together in events such as this congress and in helping us keep up our professional standards. During the next three days we are offered a great variety of lectures in all fields of Obstetrics and Gynecology. We are honoured by the outstanding speakers from the Nordic Societies and from both sides of the Atlantic. In addition to six plenary lectures, the NFOG symposium is a plenary on the global perspective of women’s health. At all other times, four concurrent symposia will be ongoing so everyone should find something of interest.

It is a special pleasure to welcome our keynote speaker Dr. Dorothy Shaw, President of FIGO (Fédération Internationale de Gynécologie et Obstétrique). This gives us a valuable opportunity to listen to the leading voice of FIGO, whose mission is to promote women’s health and safe motherhood and to raise the standards of practice in Obstetrics and Gynecology around the world.

On behalf of the local organizing committee and the NFOG Board, I warmly welcome you to this congress in Reykjavík, the capital city of Iceland, and hope that you will enjoy the scientific programme of the congress as well as the social events. Hopefully you will also have an opportunity to experience Icelandic culture and nature.

Yours sincerely,

Þóra Steingrímsdóttir
Congress president

---

Picture on cover:
The picture is a small part of the painting which shows the national flower “Holtasóley” (e; mountain avens, latin; dryas octopetala). The real size is 170x170cm. This piece of art is owned by Landsbanki who kindly gave permission to have the painting on display at Háskolabíó during the NFOG congress. The NFOG congress committee would like to express their gratitude to Landsbanki for their generous support.

About the artist:
Eggert Pétursson’s sole subject is the Icelandic flora. Conceptual rather than decorative, his unique paintings of the minute tundra flowers of Iceland’s seemingly barren landscape reveal, with dizzying effect, the universe within. Abstract at a distance, at close inspection his canvases are hyper-realistic – an infinite regression of painstaking brush detail creating each petal, stem and leaf.
Index

Welcome .................................................................. 1
Scientific committee ................................................. 4
Local organizing committee ...................................... 4
Summary of NFYOGs activities 2007 ......................... 5
NFOG National Societies ........................................... 5
Programme overview ................................................ 6
Social programme ..................................................... 13
General information .................................................. 15
Programme ............................................................... 17
Map of the congress venue Háskólabíó ..................... 44
Abstracts invited speakers ......................................... 47
Free communications ................................................ 85
Posters ...................................................................... 111
Author index ................................................................ 153
Scientific committee

Thue Bryndorf, Denmark
Oskari Heikinheimo, Finland
Alexander Smárason, Iceland
Knut Hordnes, Norway
Lars-Åke Mattsson (chairperson), Sweden

Local organizing committee

Þóra Steingrímsdóttir, president
Ósk Ingvarsdóttir, secretary general
Alexander Smárason, scientific secretary
Ólafur M Hákansson, treasurer
Arnar Hauksson, industry – sponsors
Ragnheiður Ingibjörg Bjarnadóttir
Reynir Tómas Geirsson
Dögg Hauksdóttir, NFYOG member
Hildur Harðardóttir
Jens A Guðmundsson
Summary of NFYOGs activities 2007

The NFYOG board 2007 consisted of 10 members, 2 from each of the Nordic countries Denmark, Sweden, Finland, Iceland and Norway. Three board meetings were held.

The spring meeting was held in Helsinki where the final touches to the Copenhagen seminar 2007 “Is there a future for obstetrics?” were made.

The Copenhagen seminar “Is there a future for obstetrics?” was held in the Novonordisk conference facilities in Copenhagen on June 1st and 2nd. The seminar was evaluated by the participants and NFYOG board and viewed a success. A short board meeting was held immediately after the seminar.

In the fall of 2007 a board meeting was held in Stockholm. Susanne Hesselman resigned as President when she went on maternity leave. Stig Hill was elected new President of NFYOG. Both the Swedish board members (Åsa and Susanne) resigned. Planning of the precongress seminar in Reykjavik and commencement of planning of the NFYOG seminar in 2009 was begun.

Current NFYOG board

NFYOG President
Stig Hill, Norway

Treasurer
Dógg Hauksdóttir, Iceland

Members
Paivi K Rahkola, Finland
Jatta Rautkorpi, Finland
Jens Fuglsang, Denmark
NN, Denmark
Vilde Lehland, Norway
Malin Strand, Sweden
NN, Sweden
Ágúst Ingi Ágústsson, Iceland

Regards
Stig Hill President of NFYOG

NFOG National Societies

<table>
<thead>
<tr>
<th>Country</th>
<th>Society</th>
<th>Chairmen</th>
<th>Active members (n)</th>
<th>Abstracts at NFOG Congress 2008 (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>DSOG</td>
<td>Morten Lebech</td>
<td>763 in DK, 33 abroad</td>
<td>62</td>
</tr>
<tr>
<td>Finland</td>
<td>SGY</td>
<td>Juha Tapanaainen</td>
<td>845</td>
<td>34</td>
</tr>
<tr>
<td>Iceland</td>
<td>FIFK</td>
<td>Arnar Hauksson</td>
<td>37</td>
<td>19</td>
</tr>
<tr>
<td>Norway</td>
<td>NGF</td>
<td>Rolf Kirschner</td>
<td>715</td>
<td>38</td>
</tr>
<tr>
<td>Sweden</td>
<td>SFOG</td>
<td>Charlotte Grunewald</td>
<td>1747</td>
<td>57</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>4140</td>
<td>210</td>
</tr>
</tbody>
</table>

In addition to the Chairmen of the National Societies, the NFOG board consist of the following members

President: Seija Grénman, Finland
Secretary General: Ragnheidur I. Bjarnadóttir, Iceland
Treasurer: Martin Stjernquist, Sweden
Congress President of NFOG 2008: Thóra Steingrimsdóttir, Iceland
Chairman of Scientific Committee: Lars-Åke Mattsson, Sweden
Chairman of Educational Committee: Anders Atke, Denmark
Chairman of NFYOG: Stig Hill, Norway
Chief Editor of Acta: Reynir T. Geirsson, Iceland
Webmaster (www.nfog.org): Peter Secher, Denmark
## PROGRAMME OVERVIEW

### Saturday June 14th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Precourse: Clinical Andrology: Physical examination and use of laboratory tests (CME points 8)</td>
</tr>
<tr>
<td>15:00</td>
<td>NYOG Symposium: Nordic Federation of Young Obstetricians and Gynecologists. Obstetrics, a threatened speciality. Britt-Ingiard Nesheim NO</td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>Congress Registration</td>
</tr>
<tr>
<td>18:00</td>
<td>Welcome – Get together</td>
</tr>
</tbody>
</table>

### Sunday June 15th

<table>
<thead>
<tr>
<th>Time</th>
<th>Main Hall</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Congress Registration</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Opening ceremony</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thóra Steingrímsdóttir; Seija Grénman; Alexander Smárason; Reynir Tómas Geirsson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Young Scientist Award; Best Acta Article Award; Lillehammer Stipendium; Artists: Fífillbrekkuhópurinn</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Opening lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Addressing barriers to access to sexual and reproductive health care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dorothy Shaw, FIGO president, CAN</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break / Exhibition</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>NYOG Symposium: Women’s health in a global perspective</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction; Women’s Health in a Global Perspective; Peter Hornnes DK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maternal mortality with emphasis on post partum hemorrhage; Roland Strand SE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV/AIDS and sexual and reproductive health and rights – what are the links? Jerker Liljestrand SE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>How can ob-gyn societies be useful partners in twinning? Charlotta Grunewald SE</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Plenary lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Congenital Anomalies of the Reproductive Tract; Marc Laufer US</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>Human Papilloma Virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efficacy of vaccines. Who should get them? Nubia Munoz FR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Short and long term consequences of vaccination; Jorma Paavonen FI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Should HPV testing be the primary test in screening programmes? Philip Davies FR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other indications for HPV testing; Joakim Dillner SE</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Coffee Break / Exhibition</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Ovarian cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cytoreduction for Ovarian Cancer – Are Advanced Techniques of Any Use for the Patients? William Cliby US</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer – Centralization of surgical treatment; Björn Hagen NO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prognostic markers, has anything happened during the last 25 years? Claes Högdall DK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New treatment modalities; Mark Baekelandt NO</td>
<td></td>
</tr>
<tr>
<td>17:30–18:30</td>
<td>Poster session: Authors are present by their posters and ready for discussion. Refreshments</td>
<td></td>
</tr>
</tbody>
</table>

Skills training, simulation and assessment I |
Implementation and evaluation of multiprofessional skills training in obstetrics; Jette Led Sørensen DK |
The SaFÉ Study: a randomised controlled trial of obstetric simulation training; Johanna Crofts UK |
Research into Obstetric Training – ’What are the Active Ingredients of Effective Training?’ Tim Draycott UK |
Hands on test of obstetric and gynecological simulators and assessment bench stations available all days

Hormones and wellbeing: Testosterone, Progesterone, Estrogens |
Estrogen and Cognition; Päivi Polo FI |
Progesterone and progestagens influence on memory and learning; Torbjörn Bäckström SE |
Testosterone treatment in women; Angelique Flötter Rådestad SE
<table>
<thead>
<tr>
<th>Hall 2</th>
<th>Hall 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women’s health. Free communications I</td>
<td>Ultrasound for fun</td>
</tr>
<tr>
<td>Introduction; Ove Axelsson SE</td>
<td></td>
</tr>
<tr>
<td>Epidemiological studies on safety; Helle Kieler SE</td>
<td></td>
</tr>
<tr>
<td>Animal studies on ultrasound bioeffects; Kjell Å Salvesen NO</td>
<td></td>
</tr>
<tr>
<td>Safety recommendations; Ove Axelsson SE</td>
<td></td>
</tr>
<tr>
<td>Possible advantages of 3 and 4 D ultrasound in obstetrics; Elisabeth Epstein SE</td>
<td></td>
</tr>
<tr>
<td>Prenatal diagnosis. Free communications II</td>
<td>Obesity</td>
</tr>
<tr>
<td>Morbid obesity—a silent killer? Jøran Sture Hjelmesæth NO</td>
<td></td>
</tr>
<tr>
<td>Obesity and reproduction; Tom Tanbo NO</td>
<td></td>
</tr>
<tr>
<td>Overweight and pregnancy; Tore Henriksen NO</td>
<td></td>
</tr>
</tbody>
</table>
Monday June 16th

08:15
Main Hall
Plenary lecture: Preeclampsia
James Walker UK

09:00
Skills training, simulation and assessment II
Organisation of training and integration of skill training in the curriculum on a local, regional and nation level;
Guyliane Lefebvre, CA
Simulator training and assessment in laparoscopic gynecology;
Christian Rifbjerg Larsen DK
The surgical curriculum; an evidence-based approach;
Teodor Grantcharov CA

Hall 1
Rare serious events in obstetrics
Eclampsia and Acute Fatty Liver of Pregnancy: The study of rare disorders of pregnancy using the UK Obstetric Surveillance System (UKOSS); Marian Knight UK
European Obstetric Survey System, EUROSS – The Nordic perspective; Jens Langhoff-Roos DK
Experiences from a center for pregnant women with heart disease; Marianne Johannesen DK
Hysterectomy for life-threatening peripartum haemorrhage: Study of a ‘near-miss’ event; Marian Knight UK

10:30 Coffee Break / Exhibition

11:00
Hormone treatment in the climacteric – options for today and tomorrow
Is there a "window of opportunity"? Göran Samsioe SE
Alternative treatment from an evidence based perspective; Mette Moen NO
Guidelines for HT from an international perspective; Sven Skouby DK

Severe maternal hemorrhage
Pathophysiology of severe PPH and general management; Jouni Ahonen FI
Placenta acreta; Adam Borgida, US
New methods in treating severe postpartum hemorrhage; Kjell Å. Salvesen NO

12:30 Lunch symposium – sponsored by Sanofi Pasteur MSD
Latest Clinical Update on Gardasil
Opening Introduction; Cecilia Young
GARDASIL® (Quadrivalent HPV Recombinant Vaccine): An update with four years clinical efficacy data; Nubia Munoz
Benefits of Gardasil® – on other HPV types – in women above 25 years; Ole-Erik Iversen

12:30 General Assembly – Hall 4

14:00
Plenary: Should we discontinue public funding of assisted reproduction?
Why are European laws on reproduction so similar? Paul Devroey BE
It is a mistake to limit public funding for assisted reproduction; Hans Evers NL

14:45 Genetic medicine
Genetic counselling: psychosocial issues and decision making; Heather Skirton UK
Heritable gynecological cancer; Anne-Marie Gerdes DK
Combined risk assessment for fetal aneuploidy with nuchal translucency and biochemical markers. The Danish experience, before and after the guidelines from Sundhedsstyrelsen; Ann Tabor DK

Fear of childbirth – what is it about and what can we do?
Depression and anxiety during pregnancy – prevalence and obstetric outcome; Liselott Andersson SE
Violence against women may influence childbirth; Berit Schei NO
Fear of childbirth and the wish for a cesarean; Elsa Lena Ryding, SE
Fear of childbirth can be treated and cesarean section avoided; Terhi Saisto FI

16:15 Coffee Break / Exhibition

16:45 Genetic medicine (cont’d)
Prenatal screening for fetal aneuploidy in the first trimester.
Nuchal translucency and biochemical markers; Adam Borgida US
Prenatal screening for structural malformations in the first trimester; Hulda Hjartardóttir IS

Preterm birth
Patophysiology of preterm birth; Henrik Hagberg SE
Clinical management of preterm birth; Jan Stener Jørgensen DK

20:00 Gala dinner
<table>
<thead>
<tr>
<th>Hall 2</th>
<th>Hall 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology. Free communications III</strong></td>
<td><strong>Medical abortion</strong></td>
</tr>
<tr>
<td>Cervical ripening; Helena von Hertzen WHO</td>
<td>Cervical ripening; Helena von Hertzen WHO</td>
</tr>
<tr>
<td>Contraception after abortion; Oskari Heikinheimo FI</td>
<td>Contraception after abortion; Oskari Heikinheimo FI</td>
</tr>
<tr>
<td>Medical abortion in late first trimester (9–12w); Ole-Erik Iversen NO</td>
<td>Medical abortion in late first trimester (9–12w); Ole-Erik Iversen NO</td>
</tr>
<tr>
<td>Medical abortion in very early pregnancy; Christian Fiala AT</td>
<td>Medical abortion in very early pregnancy; Christian Fiala AT</td>
</tr>
<tr>
<td>Home-use of misoprostol in medical abortion; Kristina Gemzell Danielsson SE</td>
<td>Home-use of misoprostol in medical abortion; Kristina Gemzell Danielsson SE</td>
</tr>
</tbody>
</table>

| **Fetal surveillance. Free communications IV** | **Contraception** |
| | The changing panorama of contraceptive use in the Nordic countries; Ian Milsom SE |
| The use of LNG-IUS in nulliparous women; Satu Suhonen FI | The use of LNG-IUS in nulliparous women; Satu Suhonen FI |
| Menstrual cycle suppression. An endocrine treatment and a modern | Menstrual cycle suppression. An endocrine treatment and a modern |
| solution to a modern problem; Leslie Miller UK | solution to a modern problem; Leslie Miller UK |
| Hormonal contraception and risk of venous thromboembolism. Dose | Hormonal contraception and risk of venous thromboembolism. Dose |
| reduction matters; Øyvind Lidegaard DK | reduction matters; Øyvind Lidegaard DK |

| **Lunch symposium – sponsored by Renapharma** | **Symposium – sponsored by Bayer Schering Pharma** |
| Postpartum anemia – what is the optimal treatment? | New research: Important data for counseling your |
| Erythropoiesis during pregnancy; Ivor Cavill UK | OC patients |
| IV iron vs oral iron. Results of the Norwegian Multicenter Study; | Bayer Schering Pharma: Taking a leading role in woman’s health |
| Stian Westad NO | research; Maureen Cronin (Bayer Schering Pharma) |
| IV ferric carboxymaltose. Results of the American Multicenter | EURAS: The largest European active surveillance study on the safety |
| Study; Tom Goodnough USA | and efficacy of OC use; Juergen Dinger DE |
| Blood transfusion? No, thank you!; Ivor Cavill UK | Health Authority representative; Steinar Madsen |
| | New major studies on the protective effect of OC use on ovarian |
| | and endometrial cancer; Ian Milsom SE |
| | Putting the new data into perspective for your OC patient; |
| | Maureen Cronin |

<p>| <strong>Obstetrics – focus on the mother. Free communications V</strong> | <strong>Presentation of theses</strong> |
| New trends in handling male infertility – Male infertility tests in the era of | Diet and lifestyle of women of childbearing age – Impact of cod liver oil |
| ICSI. Are genetic tests coming? Ulrik Kvist SE | consumption on maternal health, birth outcome and breast milk |
| Are sperm tests vanishing? Aleksander Giwercman SE | composition and associations between diet, lifestyle and weight gain in |
| Cryopreservation of testicular tissue; Claus Yding Andersen DK | pregnancy; Anna Sigurður Olafsdóttir IS |
| and Erik Ernst DK | Primary fallopian tube carcinoma: occurrence, risk and prognostic factors; |
| | Anna Riska FI |
| | Biochemical and Epidemiological Studies of Early-Onset and Late-Onset |
| | Preeclampsia; Anna Karin Wikström SE |
| | Total versus subtotal hysterectomy for benign uterine diseases?; |
| | Helga Gimbel DK |
| | Portal and umbilical venous distribution in the human fetus; |
| | Jörg Kessler NO |
| New trends in handling male infertility | New trends in handling male infertility – Male infertility tests in the era of |
| | ICSI. Are genetic tests coming? Ulrik Kvist SE |
| | Are sperm tests vanishing? Aleksander Giwercman SE |
| | Cryopreservation of testicular tissue; Claus Yding Andersen DK |
| | and Erik Ernst DK |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Main Hall</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td><strong>Plenary: Anatomy of the pelvic floor</strong>&lt;br&gt;Steven Swift USA</td>
<td><strong>Pediatric and adolescent gynecology</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gynecological examination of children and adolescents;&lt;br&gt;Minna Joki-Erkkilä FI</td>
</tr>
<tr>
<td>09:45</td>
<td><strong>Pregnancy, delivery and the pelvic floor</strong>&lt;br&gt;Epidemiology of female urinary incontinence and prolapse – the impact of pregnancy and delivery; Guri Rørtveit NO&lt;br&gt;Teaching doctors to diagnose and repair perineal lesions; Ranee Thakar UK&lt;br&gt;Teaching midwives to diagnose and repair perineal lesions; Sara Kindberg DK&lt;br&gt;Obstetrical lesions and the importance of the quality of primary repair; Abdul Sultan UK&lt;br&gt;Panel Debate</td>
<td>Chlamydia infection – a worry for the young women or for the gynecologist? Finn Egil Skjeldestad NO&lt;br&gt;Trends in adolescent abortion and pregnancy rates in the Nordic countries; Dan Apter FI&lt;br&gt;A model for providing contraception and other services for adolescents; Lena Marions SE</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Coffee Break / Exhibition</strong></td>
<td><strong>New technologies in pelvic surgery – what is the evidence?</strong>&lt;br&gt;What is the best sling for stress urinary incontinence?&lt;br&gt;Antti Valpas FI&lt;br&gt;The use of implants in surgery for pelvic organ prolapse – evidence or marketing? Daniel Altman SE&lt;br&gt;Emerging complications with novel technologies in pelvic surgery; Eckhard Petri DE&lt;br&gt;Scientific, ethical and legal implications of introducing new technologies in pelvic surgery; Gunnar Lose DK</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Closing ceremony</strong>&lt;br&gt;Prizes awarded for best presentations</td>
<td><strong>Refreshments</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hall 2</td>
<td>Hall 3</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td></td>
</tr>
</tbody>
</table>
| **Premenstrual syndrome/Premenstrual dysphoric disorder**  
  Etiology and pathogenesis of PMDD/PMS; Torbjörn Bäckström SE  
  Treatment of premenstrual dysphoric disorder; Inger Sundström Poromaa SE | **Obstetrics – focus on the fetus. Free communications VI** |
| **Postterm pregnancies**  
  Induction of post term pregnancy – time to reconsider?  
  Jacob Nakling NO  
  Routine induction of labour at 41 weeks gestation:  
  Nonsensus Consensus; Kåre Augensen NO  
  Management of post-date pregnancy: Todays’ evidence; Ulla Britt Wennerholm SE  
  Induction of labour or serial antenatal fetal monitoring in post-term pregnancy? A randomised controlled trial; Runa Heimstad | **Gynecology. Free communications VII** |
SOCIAL PROGRAMME

Saturday June 14th

18:00–20:00  Welcome and get together party
Welcome and get-together party with entertainment and light refreshments is at Listasafn Reykjavíkur – Reykjavík Art Museum, The Harbour House.

The Harbour House, housed in the former Warehouses of the Port of Reykjavík, has diverse exhibitions of contemporary and experimental art, both Icelandic and international. The museum also houses the Erró Collection, a large collection of works by one of Iceland’s most celebrated modern artists – there are varying exhibitions on parts of this collection at the Museum.

All participants and exhibitors are welcome.

Please note that special transfer from hotels or congress venue is NOT provided

Sunday June 15th

18:30–23:00  Blue Lagoon tour with dinner
The Blue Lagoon is a unique wonder of nature, a pool of natural mineral rich geothermal seawater in the middle of a lava field. The lagoon is rich in a unique natural combination of minerals. Blue-green algae and white Silica mud form natural sediment on the bottom of the lagoon and give the lagoon its soft, milky, aquamarine colour.

The Blue Lagoon was created when hot water from the nearby “Svartsengi” geothermal power plant that formed due to heat exchange was discharged into the adjacent lava field.

A visit to the Blue Lagoon is an invigorating and exciting experience.

After relaxing bathe in the Blue Lagoon which is truly a unique experience a dinner will be served in the restaurant.

Please note that swimming suits and towels are NOT provided.

Departure from Háskólabíó – the Congress Venue

Price per pers: ISK 9,100,-

Tickets can be obtained at the Registration Desk

Monday June 16th

20:00–01:00  Gala dinner
The Gala dinner is at Hilton Reykjavik Nordica which is located in Reykjavik, about 5 minutes drive from the Congress Venue.

A 3 course delicious dinner with wine will be served. Icelandic artists will perform during dinner and the band “Hunang” will play for dance.

Please note that special transfer from hotels is NOT provided to / from the Gala dinner.

Price per pers: ISK 8,000,-

Tickets can be obtained at the Registration Desk

Tuesday June 17th

14:00–19:00  The Golden Circle
On this tour you will see the world-famous Geysir geothermal field and Gullfoss, the queen of Icelandic waterfalls. The Geysir geothermal field has spouting springs of various formations, bubbling hot water and exploding geysers while at Gullfoss you are given the opportunity to stand next to the amazing waterfall, watching its enormous quantities of water tumble violently into a deep, meandering gorge.

Lunch and refreshments not included

Includes: Bus fare and guidance in English.

Departure from Háskólabíó – the Congress Venue

Price per person: ISK 5,600,-

Tickets can be obtained at the Registration Desk.
Tuesday June 17th

14:00–17:00 Pingvellir tour with Herb introduction

Major events in the history of Iceland have taken place at Þingvellir, a declared National Park in 1930 and all Icelanders hold the place in high esteem. Today, Pingvellir is a protected national shrine. A law was passed designating Þingvellir as “a protected national shrine for all Icelanders, the perpetual property of the Icelandic nation under the preservation of a parliament, never to be sold or mortgaged.”

The Pingvellir area is part of a fissure zone running through the country, being situated on the tectonic plate boundaries of the Mid-Atlantic Ridge. The faults and fissures of the area make evident the rifting of the earth’s crust. Today, Pingvellir is one of the most frequently visited tourist sites in the country. Each year, thousands of visitors go there to become better acquainted with Iceland’s greatest historical site and jewel of nature. On this tour you will also be introduced to Icelandic herbs.

The group gathers around a table covered with Icelandic plants and herbs such as: Iceland moss, seaweed, angelica, and more. A guide explains the medicinal properties of those plants and gives examples of how the Icelanders use them to improve their health. The taste buds are teased with a refreshing herbal tea, some seaweed, warm milk infused with Iceland moss, and other traditional Icelandic herbal delicacies. The participants then get the secret recipe of the “sorcerer’s lupine root drink” plus a small goodbye present before heading back to Reykjavik.

Departure from Háskólabíó – the Congress Venue
Price per person: ISK 7,100,-
Tickets can be obtained at the Registration Desk.

Tuesday June 17th

14:00–18:00 Blue Lagoon tour

The Blue Lagoon is a unique wonder of nature, a pool of natural mineral rich geothermal seawater in the middle of a lava field. The lagoon is rich in a unique natural combination of minerals. Blue-green algae and white Silica mud form natural sediment on the bottom of the lagoon and give the lagoon its soft, milky, aquamarine colour.

The Blue Lagoon was created when hot water from the nearby “Svartsengi” geothermal power plant that formed due to heat exchange was discharged into the adjacent lava field.

A visit to the Blue Lagoon is an invigorating and exciting experience
Please note that swimming suits and towels are NOT provided.
Departure from Háskólabíó – the Congress Venue
Price per person: ISK 5,600,-
Tickets can be obtained at the Registration Desk.

Tuesday June 17th

13:00 Closing Ceremony & Farewell drink by invitation of the organizing committee

Sparkling wine, chocolate strawberries and marzipan sweeties are offered in the foyer after the Ceremony – as a NFOG 2008 Congress farewell drink and a celebration of the Icelandic Independence Day June 17th.
GENERAL INFORMATION

The Congress is held at Háskólabíó, The University Cinema Complex – www.haskolabio.is
Háskólabíó is adjacent to the Radisson SAS Saga Hotel and close to the city centre of Reykjavík.
All sessions will take place in the lecture halls of Háskólabíó and the exhibition is housed in the foyer.
The address is: Háskólabíó, v/ Hagatorg, 107 Reykjavík – Iceland
Tel: +354-525 5400, fax +354-525 5401
Contact person: Mr. Þorvaldur Kolbeins, thorri@haskolabio.is, mobile: +354-893 9050

Banking Facilities
A bank is located in the same building as Háskólabíó. Opening hours are Monday to Friday from 09:15–16:00.
ATM is located outside the building.

Chairs
Please be present in your session hall at least 10 minutes prior to your session. It is important that the session stay
on schedule so that individuals who want to hear a specific talk may do so without concerns of time. It is thus vital
that all speakers observe their time allotment.

Congress Badges
Your personal badge is your entrance ticket to all sessions and you are asked to wear it throughout the congress.
Should you misplace your badge a replacement can be obtained at the Congress hospitality desk.
Organizing and Scientific committees have badges with yellow stripe and exhibitors with blue.

Credit Cards
Commonly accepted cards in hotels, shops, restaurants and at the Congress hospitality desk: Visa, MasterCard,
EuroCard, Diners and American Express.

Emergency
Telephone number: 112

Excursions
Excursions for participants and accompanying persons are available and detailed information and tickets can be
obtained at the Congress hospitality desk.

Commercial Exhibition
The exhibition is held in the foyer of the lecture halls and is open throughout the congress.
List of the exhibitors and a map of the venue is in the programme. Exhibitors have badges with blue stripe.

Hospitality and Registration Desk
The Congress Reykjavík is in charge of the registration, accommodation bookings, social arrangements, exhibition
and excursions and general information. Tickets for social events and excursions can be obtained at the hospitality
desk. The desk remains open during the congress.
Telephone / mobile: Lára +354-896 6075, Tobba +354-862 4752, Imma +354-897 5559

Internet Café
Internet Café with 6 computers will be located in the foyer of the Main Hall. Please observe the time limit of 10
minutes for each guest if there are other waiting.
The Internet Café is sponsored by Bayer Schering Pharma.

Language
All presentations are in English, no simultaneous interpretation is provided.

Lunches and coffee breaks
Lunches and coffee, tea and refreshments are included in the registration fee and are served in the exhibition area.
Poster Display, set-up and removal
Posters should be mounted by the presenters before 13:00, Sunday June 15 and dismantled on Tuesday June 17, before 12:00.
Assistant will be present for any information or help on Sunday June 15, between 08:00–13:00.
Posters are numbered in the programme and the boards accordingly. Please take notice of that before hanging up your poster.
Posters left on poster boards will be removed by the organizer who can not be held liable for any loss or damage to posters beyond the official removal times.
Posters are displayed in the foyer of the lecture halls.

Poster Session
Time: Sunday June 15, 17:30–18:30
Author / authors are present by their poster and ready for discussion.
Light refreshments (wine & cheese) will be served during the Poster session.

Professional Congress Organizer – PCO
Congress Reykjavik, Conference Management Services Ltd. is the official organizing agency for the congress.
The address is: Congress Reykjavik, Engjateigur 5, IS-105 Reykjavik,
tel: +354-585 3900, fax: +354-585 3901
e-mail: congress@congress.is, www.congress.is

Smoking Policy
Smoking is not allowed inside the Congress Venue.

Speakers
All speakers are asked to present themselves to the technician with their presentation at least one hour before the beginning of their session. Please note that you need to hand in your power point presentations on a CD-ROM or USB key. Assistance can be obtained in the speaker's room.

Taxi
Taxis are available outside all hotels and in the City Centre at a reasonable price.
You can call a taxi on +354-561 0000
PROGRAMME

Saturday June 14th

09:00–17:00  Precourse: Clinical Andrology. Physical examination and use of laboratory tests (CME points 8)
15:00–17:00  NFYOG Symposium: Nordic Federation of Young Obstetricians and Gynecologists. Obstetrics, a threatened speciality. Britt-Ingrid Nesheim, Norway
18:00–20:00  Welcome and Get-together party

Sunday June 15th

09:00–09:30  Opening Ceremony
Main Hall
Thóra Steingrímsdóttir
Seija Grénman
Alexander Smárason
Reynir Tómas Geirsson

Artists: Fífillbrekkuhópurinn
Young Scientist Award
Best Acta Article Award
Lillehammer scholarship

09:30–10:30  Opening lecture
Main Hall
Chair: Reynir Tómas Geirsson

IS-001 Addressing barriers to access to sexual and reproductive health care
Dorothy Shaw
FIGO president, University of British Columbia, VANCOUVER, Canada

10:30–11:00 Coffee Break / Exhibition

11:00–12:30  NFYOG Symposium: Women’s health in a global perspective
Main Hall
Chairs: Seija Grénman and Unni Kirste

11:00–11:20  IS-002 Women’s Health in a Global Perspective
Peter Hornnes
Hvidovre University Hospital, HVIDOVRE, Denmark

11:20–11:40  IS-003 Maternal mortality with emphasis on post partum haemorrhage (PPH)
Roland Strand
Kvinnokliniken, ESKILSTUNA, Sverige

11:40–12:00  IS-004 HIV/AIDS and sexual and reproductive health and rights – what are the links?
Jerker Liljestrand
Department of Health Sciences/Division of Social Medicine and Global Health, MALMÖ, Sweden

12:10–12:20  IS-005 How can ob-gyn societies be useful partners in twinning?
Charlotte Grunewald
SFOG, Dpt ObGyn South General Hospital, NACKA, Sweden

12:20–12:30 Discussion
12:30–13:30 Lunch Break
13:30–14:15 **Plenary lecture**

*Chair: Mette Moen*

**IS-006 Congential Anomalies of the Reproductive Tract**
Marc Laufer
Children’s Hospital Boston, BOSTON, United States of America

14:15–15:45 **Human Papilloma Virus**

*Chairs: Kristján Sigurðsson and Ole Erik Iversen*

14:15–14:35 **IS-007 Efficacy of HPV vaccines. Who should get them?**
Nubia Muñoz
Emeritus professor at the National Cancer Institute of Colombia, Colombia / Lyon, France

14:35–14:55 **IS-008 Short and long term consequences of HPV vaccination**
Jorma Paavonen
Helsinki University Central Hospital, HELSINKI, Finland

14:55–15:15 **IS-009 Should HPV testing be the primary test in screening programmes?**
Philip Davies
European Cervical Cancer Association, France

15:15–15:35 **IS-010 Current and future indications of HPV testing**
Joakim Dillner
Lund University, MALMÖ, Sweden

15:35–15:45 **Discussion**

14:15–15:45 **Skills training, simulation and assessment I**

*Chairs: Rolf Kirschner and Jan Stener Jørgensen*

14:15–14:40 **IS-011 Implementation and evaluation of multiprofessional skillstraining in obstetrics**
Jette Led Soerensen
Rigshospitalet, COPENHAGEN, Denmark

14:40–15:05 **IS-012 The SaFE Study: a randomised controlled trial of obstetric simulation training**
Joanna Crofts
Southmead Hospital, BRISTOL, United Kingdom

15:05–15:30 **IS-013 Research into Obstetric Training – ‘What are the Active Ingredients of Effective Training?’**
Tim Draycott
Southmead Hospital, BRISTOL, United Kingdom

15:30–15:45 **Discussion**
Hands on test of obstetric and gynecological simulators and assessment bench stations available all days

14:15–15:45 **Womens health. Free communications I**

*Chairs: Satu Suhonen and Unni Kirste*

14:15–14:25 **WH1 Hormone Therapy and risk of Myocardial Infarction. Effect modification by concomittant medication for diabetes, hypertension, cholesterol and arrhythmia. A National register study**
Ellen Løkkegaard¹, Anne Helms Andreasen², Rikke Kart Jacobsen², Lars Hougaard Nielsen², Carsten Agger², Øivind Lidegaard¹
¹Glostrup Hospital, GLOSTRUP, Danmark
²Research Centre for Prevention and Health, The Capital Region of Denmark, GLOSTRUP, Danmark
³Gynaecological Clinic, Rigshospitalet, COPENHAGEN, Danmark
14:25–14:35 **WH2 Prevalence of psychological, physical and sexual abuse in a national study in young men and women in Sweden**  
Ingela Danielsson¹, Helena Blom², Carin Nilses³, Ulf Högberg⁴, Gun Heimer⁵  
¹ Umeå University, UMEÅ, Sweden  
² Department of Obstetrics and Gynecology, Sundsvall Hospital, SUNDSVALL, Sweden  
³ Department of Clinical Science Obstetrics and Gynecology, UMEÅ, Sweden  
⁴ Department of Clinical Science Obstetrics and Gynecology, UMEÅ, Sweden  
⁵ National Centre for Knowledge on Men’s Violence against Women, UPPSALA, Sweden

14:35–14:45 **WH3 Risk consumption of alcohol among students in secondary schools exposed to emotional, physical and sexual violence**  
Carin Nilses¹, Helena Blom², Ingela Danielsson¹  
¹ Department of Clinical Science Obstetrics and Gynecology, UMEÅ, Sweden  
² Department of Obstetrics and Gynecology, Sundsvall Hospital, SUNDSVALL, Sweden

14:45–14:55 **WH4 Gynecologic fistula following sexual violence**  
Mathias Onsrud¹, Solbjørg Sjøveian¹, Denis Mukwege²  
¹ Ullevål University Hospital, OSLO, Norge  
² Panzi University Hospital, BUKAVU, Congo

14:55–15:05 **WH5 Injury documentation, forensic sampling and legal outcome in police reported sexual assaults of adult women**  
Cecilie Therese Hagemann¹, Lise Eileen Stene¹, Kari Ormstad¹, Berit Schei¹  
¹ St Olavs Hospital HF, TRONDHEIM, Norge  
² Stavanger University Hospital, STAVANGER, Norge  
³ Institute of Forensic Medicine, University of Oslo, OSLO, Norge  
⁴ Faculty of Medicine, Norwegian University of Science and Technology, TRONDHEIM, Norge

15:05–15:15 **WH6 Chlamydia trachomatis seroprevalence rates in Finland over two decades**  
Jorma Paavonen¹, E Lyytikäinen², M Kaasila³, E Hiltunen-Back¹, M Lehtinen³, K Tasanen³, H-M Surcel¹, P Koskela¹, J Paavonen¹  
¹ Helsinki University Central Hospital, HELSINKI, Finland  
² National Public Health Institute, OULU AND KUOPIO, Finland  
³ National Public Health Institute, KUOPIO AND OULU, Finland  
⁴ University of Tampere, School of Public Health, TAMPERE, Finland  
⁵ University of Oulu, Department of Dermatology, OULU, Finland

15:15–15:25 **WH7 Sexuality, fertility and outcome of pregnancies in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency**  
Kerstin Hagenfeldt¹, Per-Olof Janson¹, Gundela Holmdahl¹, Henrik Falhammar¹, Helena Filipsson³, Louise Frisén¹, Marja Thorén¹, Agneta Nordenskjöld¹  
¹ Karolinska Institutet, STOCKHOLM, Sweden  
² Dep Obstet/Gynecol, Sahlgrenska Hospital, GÖTEBORG, Sweden  
³ Pediatric Surgery, Queen Silvia Children’s Hospital, GÖTEBORG, Sweden  
⁴ Dep Endocrinology/Metabolism & Diabetes, Karolinska Institutet, STOCKHOLM, Sweden  
⁵ Dep of Endocrinology, Sahlgrenska University Hospital, GÖTEBORG, Sweden  
⁶ Dep of Clinical Sciences, Div of Psychiatry Danderyd’s Hospital, STOCKHOLM, Sweden  
⁷ Dep Molecular Med & Surgery and Pediatric Surgery, Karolinska Institutet, STOCKHOLM, Sweden

14:15–15:45 **Ultrasound for fun**  
Hall 3  
**Chairs:** Bjørn Backe and Isis Amer Wåhlin

14:15–14:25 **IS-014 Introduction**  
Ove Axelsson  
Uppsala University, UPPSALA, Sweden

14:25–14:45 **IS-015 Epidemiological studies on safety**  
Helle Kieler  
Karolinska Institutet, STOCKHOLM, Sweden
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45–15:00</td>
<td>IS-016 Animal studies on ultrasound bioeffects</td>
</tr>
<tr>
<td></td>
<td>Kjell Salvesen</td>
</tr>
<tr>
<td></td>
<td>National Center for Fetal Medicine, TRONDHEIM, Norway</td>
</tr>
<tr>
<td>15:00–15:10</td>
<td>IS-017 Safety recommendations</td>
</tr>
<tr>
<td></td>
<td>Ove Axelsson</td>
</tr>
<tr>
<td></td>
<td>Uppsala University, UPPSALA, Sweden</td>
</tr>
<tr>
<td>15:10–15:30</td>
<td>IS-018 Possible advantages of 3 and 4 D ultrasound in obstetrics</td>
</tr>
<tr>
<td></td>
<td>Elisabeth Epstein</td>
</tr>
<tr>
<td></td>
<td>Clinical sciences, Lund, LIMHAMN, Sweden</td>
</tr>
<tr>
<td>15:30–15:45</td>
<td>Discussion</td>
</tr>
<tr>
<td>15:45–16:15</td>
<td>Coffee Break / Exhibition</td>
</tr>
</tbody>
</table>

16:15–17:30 Ovarian cancer  

**Main Hall**

*Chairs: Bengt Tholander and Björn Hagen*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15–16:45</td>
<td>IS-019 Cytoreduction for Ovarian Cancer – Are Advanced Techniques of Any Use for the Patients?</td>
</tr>
<tr>
<td></td>
<td>William Cliby</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic, ROCHESTER, MINNESOTA, USA</td>
</tr>
<tr>
<td>16:45–17:00</td>
<td>IS-020 Ovarian cancer – Centralization of surgical treatment</td>
</tr>
<tr>
<td></td>
<td>Bjørn Hagen</td>
</tr>
<tr>
<td></td>
<td>Trondheim Univ. Hosp., TRONDHEIM, Norway</td>
</tr>
<tr>
<td>17:00–17:15</td>
<td>IS-021 Prognostic markers, has anything happened during the last 25 years?</td>
</tr>
<tr>
<td></td>
<td>Claus Hegdall</td>
</tr>
<tr>
<td></td>
<td>Rigshospitalet, COPENHAGEN Ø, Denmark</td>
</tr>
<tr>
<td>17:15–17:30</td>
<td>IS-022 New treatment modalities</td>
</tr>
<tr>
<td></td>
<td>Mark Baekelandt</td>
</tr>
<tr>
<td></td>
<td>Norwegían Radium Hospital, Norway</td>
</tr>
</tbody>
</table>

16:15–17:30 Hormones and wellbeing: Testosterone, Progesterone, Estrogens  

**Hall 1**

*Chairs: Kerstin Hagenfeldt and Risto Erkkola*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15–16:35</td>
<td>IS-023 Estrogen and Cognition</td>
</tr>
<tr>
<td></td>
<td>Päivi Polo-Kantola</td>
</tr>
<tr>
<td></td>
<td>Turku University Hospital, TURKU, Finland</td>
</tr>
<tr>
<td>16:35–16:55</td>
<td>IS-024 Progestosterone and progestagens influence on memory and learning</td>
</tr>
<tr>
<td></td>
<td>Torbjörn Bäckström</td>
</tr>
<tr>
<td></td>
<td>Umeå University Hospital, UMEÅ, Sweden</td>
</tr>
<tr>
<td>16:55–17:15</td>
<td>IS-025 Testosterone treatment in women</td>
</tr>
<tr>
<td></td>
<td>Angelique Flöter Rådestad</td>
</tr>
<tr>
<td></td>
<td>Karolinska University Hospital, STOCKHOLM, Sweden</td>
</tr>
<tr>
<td>17:15–17:30</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

16:15–17:35 Prenatal diagnosis. Free communications II  

**Hall 2**

*Chairs: Thue Bryndorf and Jörg Kessler*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Christina H. F. Vestergaard, Øjvind Lidegaard, Ann Tabor</td>
</tr>
<tr>
<td></td>
<td>Rigshospitalet, KØBENHAVN Ø, Denmark</td>
</tr>
<tr>
<td>16:25–16:35</td>
<td>PD2 Knowledge and understanding of prenatal screening and testing before and after the introduction of information booklet</td>
</tr>
<tr>
<td></td>
<td>Vigdis Stefánsdóttir¹, Hildur Hardardóttir¹, Jón Jóhannes Jónsson¹, Heather Skirton¹</td>
</tr>
<tr>
<td></td>
<td>¹Landspitali University Hospital, REYKJAVIK, Iceland</td>
</tr>
<tr>
<td></td>
<td>²University of Plymouth, TAUNTON, United Kingdom</td>
</tr>
</tbody>
</table>
16:35–16:45 **PD3 Improved performance of first-trimester screening for trisomy 21 with the double test taken before a gestational age of 10 weeks**
Ida Kirkegaard¹, Ola Bjørn Pedersen¹, Niels Uldbjerg¹, Niels Torring¹
¹Dept. Gynecology and Obstetrics, AARHUS C, Denmark
²Dept. Clinical Biochemistry, AARHUS, Denmark

16:45–16:55 **PD4 First trimester screening in IVF/ICSI pregnancies: The significance of gestational dating by oocyte retrieval or crown rump length**
Anne Cathrine Gjerris¹, A Loft¹, A Piborg¹, A Tabor¹, M Christiansen¹
¹Rigshospitalet, Copenhagen University Hospital, COPENHAGEN, Denmark
²The Fertility Clinic, Rigshospitalet, University Hospital, COPENHAGEN, Denmark
³Department of Fetal Medicine, Rigshospitalet University Hospital, COPENHAGEN, Denmark
⁴Department of Clinical Biochemistry, Statens Serum Institut, COPENHAGEN, Denmark

16:55–17:05 **PD5 ADAM12 is an efficient first trimester maternal serum marker for Down syndrome**
Michael Christiansen¹, Kasper Pihl¹, Paula Hedley¹, Severin Larsen¹, Lone Krebs¹, Torben Larsen¹
¹Statens Serum Institut, COPENHAGEN, Denmark
²Holbæk Sygehus, HOLBÆK, Denmark

17:05–17:15 **PD6 A new population based term prediction method – evaluation of the FL-based predictions**
Inger Økland¹, Håkon K. Gjessing¹, Per Grøttum¹, Torbjørn M. Eggebø¹, Sturla H. Eik-Nes¹
¹Stavanger University Hospital, STAVANGER, Norge
²Norwegian Institute of Public Health, OSLO, Norge
³University of Oslo, OSLO, Norge
⁴National Center for Fetal Medicine, Norwegian University of Science and Technolo, TRONDHEIM, Norge

17:15–17:25 **PD7 Neonatal alloimmune thrombocytopenia (NAIT) in Norway: Under diagnosed with non-screening versus a general screening program. Maternal anti-HLA class 1 antibodies as cause of neonatal alloimmune thrombocytopenia (NAIT) – no longer a myth?**
Heidi Tiller, Mette Kjær Killie, Bjørn Skogen, Pål Øian, Anne Husebekk
University Hospital of North Norway, TROMSO, Norway

17:25–17:35 **PD8 Prenatal ultrasound and childhood brain tumours**
Karin Stalberg¹, Bengt Haglund¹, Ove Axelsson¹, Sven Cnattingius¹, Susan Pfeifer¹, Helle Kieler¹
¹Uppsala Universitet, UPPSALA, Sverige
²Centre for Epidemiology, National Board of Health and Welfare, STOCKHOLM, Sverige
³Department of Women’s and Children’s Health, Obstetrics and Gynecology, UPPSALA, Sverige
⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, STOCKHOLM, Sverige
⁵Department of Genetics and Pathology, Rudbeck Laboratory, UPPSALA, Sverige
⁶Centre for Pharmacoepidemiology, Karolinska Institutet, STOCKHOLM, Sverige

**Obesity**

Chairs: Helena Strevens and Elisabeth Darj

16:15–16:35 **IS-026 Morbid obesity – silent killer?**
Jøran Hjelmesæth
Morbid Obesity Centre, TØNSBERG, Norway

16:35–16:55 **IS-027 Obesity and reproduction**
Tom Tanbo
Rikshospitalet University Hospital, OSLO, Norway

16:55–17:20 **IS-028 OVERWEIGHT AND PREGNANCY**
Tore Henriksen
University of Oslo, OSLO, Norway

17:20–17:30 Discussion
17:30–18:30  Poster session – Authors are present by their posters and ready for discussion

Refreshments

Acta Prize Winner

P001 Placental abruption: risk factors and biochemical markers
Tikkanen M, Paavonen J, Nuutila M, Hilesmaa V, Ylikorkala O
Department of Obstetrics and Gynecology, University of Helsinki, Finland

P002 Iceland – Prenatal screening in the first trimester
Hildur Harðardóttir, María Heinsdóttir, Hulda Hjartardóttir, Jón Jóhannes Jónsson
Landspitali University Hospital, REYKJAVÍK, Iceland

P003 Declining number of invasive procedures for prenatal aneuploidy diagnosis
Hildur Harðardóttir, Hulda Hjartardóttir, Kristín Rut Haraldsdóttir, María Heinsdóttir
Landspitali University Hospital, REYKJAVÍK, Iceland

P004 Maternal serum leptin is not a first trimester marker of foetal Down syndrome
Paula Hedley, Michael Christiansen
Statens Serum Institut, COPENHAGEN, Denmark

P005 Need for chromosomal diagnosis in single umbilical artery
Lone Laursen, Ole Mogensen
University Hospital of Odense, ODENSE, Denmark

P006 Title Ascertainment Deficiencies of the Swedish Birth Defects Registry and the Incidence of Cleft Lip/Palate and Spina Bifida in Sweden
Hashem Amini1, Ove Axelson1, Birgitta Ollars1, Göran Annerén2
1Department of Women and Children’s Health Uppsala University, UPPSALA, Sweden
2Swedish Registry of Birth Defects, National Board of Health and Welfare, STOCKHOLM, Sweden

P007 Obese women have an increased risk for erroneous ultrasound dating in second trimester
Marija Simić1, Isis Amer-Wahlin1, Karel Marsal1, Karin Källén4
1Karolinska University hospital, STOCKHOLM, Sverige
2Karolinska institutet, STOCKHOLM, Sverige
3Dept of Ob and Gyn, University Hospital Lund, LUND, Sverige
4Tornblad institute, University of Lund, LUND, Sweden

P008 Intervention program for obese pregnant woman
Elisabeth Storck Lindholm, Margareta Norman, Daniel Altman
Danderyds sjukhus, STOCKHOLM, Sweden

P009 Delivery complications: The role of lifestyle related factors
Nanna Voldner1, Kathrine Froslie1, Kari Bo1, Lene Haakstad1, Jens Bollerslev1, Tore Henriksen1
1Rikshospitalet Medical Centre, OSLO, Norway
2Norwegian School of Sport Science, OSLO, Norway

P010 Maternal metabolic syndrome and macrosomia in healthy Norwegian gravida
Nanna Voldner, Elisabeth Qvigstad, Kathrine Froslie, Tore Henriksen, Jens Bollerslev
Rikshospitalet Medical Centre, OSLO, Norway

P011 A longitudinal study of six humoral inflammatory markers in pregnancy. Relation to obesity
Camilla Hoff, Katrine Frey Froslie, Nanna Voldner, Kristin Godang, Jens Bollerslev, Tore Henriksen
Rikshospitalet, OSLO, Norge

P012 Pregnancy outcome in overweight and obese women
Ólöf Elíasdóttir, Hildur Harðardóttir, Þórður Þórkelsson
University of Iceland, REYKJAVÍK, Iceland
P013 The Effect of Pre-pregnancy Body Mass Index (BMI) and Weight Gain in Pregnancy on Cesarean Section Rate in Spontaneous Labour
Alexander Smaráson1, Tatjana Aberle1, Ingibjörg Jónsdóttir2
1Institution of Health Science Research, University of Akureyri, AKUREYRI, Iceland
2FSA, University Hospital, AKUREYRI, Iceland

P014 The relation between birth weight and hypertension among Danish nurses with and without a familial pre-disposition to obesity
Rie Adser Virkus1, Berit Heitmann2, Ellen Christine Løkkegaard1, Thomas Bergholdt1, Morten Hedegaard1, Bent Ottesen1
1Hillerød Hospital, HILLERØD, Denmark
2Research Unit for Dietary Studies and the Danish Epidemiology Science Center at, COPENHAGEN, Denmark

P015 Does coffee intake during pregnancy prevent gestational diabetes mellitus?
Birgitte Bruun Nielsen, Per Ovesen, Tine Brink Henriksen
Aarhus University Hospital, Skejby, AARHUS, Denmark

P016 Management of insulin dependent diabetes mellitus in pregnancy during a 26 year period at Danderyd Hospital
Margareta Nyman1, Elisabeth Lindholm1, Per-Eric Lins1, Margareta Norman1
1Danderyd Hospital, STOCKHOLM, Sweden
2Sweden

P017 Blood glucose home monitoring-based therapy in gestational diabetes leads to reduced number of macrosomic infants
Jukka Uotila, Sirkku Tulokas
Tampere University Hospital, TAMPERE, Finland

P018 Changes of endothelial function in preeclampsia during pregnancy, early and late postpartum
Rangeen Rafik Hamad1, Maria J Eriksson1, Katarina Bremme1
1Karolinska Institutet, STOCKHOLM, Sweden
2Department of Clinical Physiology, KAROLINSKA HOSPITAL/STOCKHOLM, Sweden

P019 Ang-1/Ang-2 ratio as a predictive biomarker for preeclampsia
Helena Åkerud1, Anders Larsson1, Mats Olovsson1
1Dept of Women’s and Children’s Health, Uppsala University, UPPSALA, Sweden
2Dept of Medical Sciences, Clinical Chemistry, UPPSALA, Sweden
3Dept of Women’s and Childrens Health, Uppsala University, UPPSALA, Sweden

P020 Maternal serum leptin is a first trimester marker of pre-eclampsia
Paula Hedley, Michael Christiansen
Statens Serum Institut, COPENHAGEN, Denmark

P021 Case report of severe thrombocytopenia in pregnancy
Kadi Ploom
East Tallinn Central Hospital, TALLINN, Estonia

P022 Q-fever during pregnancy: a case report
Lise Lotte Torvin Andersen, Kirsten Marie Schiøtt
Odense University Hospital, ODENSE M, Denmark

P023 Acute Q-fever in pregnancy – A matter of concern to Obstetricians in the Nordic Countries?
Kirsten Marie Schiøtt, Lise Lotte Torvin Andersen
Odense University Hospital, ODENSE, Denmark
P024 Uterine artery pseudoaneurysm resulting from hidden uterine rupture misinterpreted as a lower uterine segment necrotic myoma
Ajlana Mulic-Lutvica
Institute of Women’s and Children’s Health, UPPSALA, Sverige

P025 Pre-pregnancy transabdominal cerclage in women with previous second trimester deliveries
Lea Langhoff Thuesen, Birgitte Rode Diness, Jens Langhoff-Roos
Rigshospitalet, COPENHAGEN, Denmark

P026 The growth hormone axis in twin pregnancies
Jens Fuglsang, Sanne Fisker, Niels Møller, Per Ovesen
1Aarhus Universitetshospital, Skejby, & Regionshospitalet Herning, AARHUS N, Danmark
2Medical Research Laboratories, Aarhus University Hospital, AARHUS C, Danmark
3Gynaecological/Obstetrical Dept. Y, Aarhus University Hospital, AARHUS N, Danmark

P027 Nitric oxide induced morphological changes in the human uterine cervix studied by electron microscopy
Maria Bullarbo, Erling Ekerhovd, Nina Radulovic, Anders Norström
Institution of clinical sciences, GÖTEBORG, Sweden

P028 Vaginal nitro induces cervical nitric oxide release in women postterm
Mervi Väisänen-Tommiska, Tomi Mikkola, Olavi Ylikorkala
Helsinki University Central Hospital, HELSINKI, Finland

P029 Cervical biopsies can be send by mail for assessment of cervical incompetence
Iben Sundtoft, Niels Uldbjerg, Ole Bjarne Christiansen, Steffen Sommer
1Aarhus University Hospital Skejby, AARHUS N, Denmark
2Department of Obstetrics and Gynecology, Aarhus University Hospital Skejby, DK-8200 AARHUS N, Denmark
3The Fertility Clinic, University Hospital Copenhagen, Rigshospitalet, COPENHAGEN, Denmark
4Department of Obstetrics and Gynecology, Horsens Regional, DK-8700 HORSENS, Denmark

P030 Comparison of Three Modes of Administration of Prostaglandin for Induction of Labour
Morten Beck Sorensen, Clair Evans, Ada Ekpe, Christina Cotzias
1West Middlesex University Hospital, LONDON, United Kingdom
2West Middlesex Hospital, LONDON, United Kingdom

P031 Association between lactate concentration in amniotic fluid (AF) and labour dystocia
Eva Wiberg-Itzel, Lennart Nordstrom
Karolinska Institute, DANDERYD, Sverige

P032 Decreased Cesarean Section Rate after the Introduction of Robson’s 10 Group Classification System
Jón Gyfason, Ásta Eymundsdóttir, Ingibjörg Jónsdóttir, Alexander Smárason
1FSA University Hospital, AKUREYRI, Iceland
2Institution of Health Science Research, University of Akureyri, AKUREYRI, Iceland

P033 Vaginal birth following one prior cesarean section
Brynhildur Tinna Birgisdóttir, Hildur Harðardóttir, Ragnheiður Bjarnadóttir, Þórður Hókelsson
Landspitali University Hospital, REYKJAVIK, Iceland

P034 Continuous uterine massage in cases with retained placenta reduces blood loss?
Maria Jonsson, Ulf Hanson, Annie Sigfusdottir
1Department of Women’s and Children’s Health Uppsala University Uppsala, UPPSALA, Sweden
2Department of Obstetrics and Gynecology, Uppsala University Hospital, UPPSALA, Sweden

P035 Fire drills in obstetric emergencies
Pernille Lottrup, Mette Simonsen, Hanne Kjaergaard, Marianne Johansen, Bent Ottesen, Jette Led Soerensen
The Juliane Marie Centre for Children, Women and Reproduction Copenhagen Univers, COPENHAGEN Ø, Danmark
P036 Breech delivery
Jatta Tuohimaa, Tuija Heikkinen
Turku University Hospital, TURKU, Finland

P037 Post-partum urinary tract infection
Rita Andersen Leth1, Jens Kjølseth Møller1, Reimar W. Thomsen2, Niels Uldbjerg3, Mette Nørgaard1
1Aarhus University Hospital, Skejby, AARHUS N, Denmark
2Aarhus University Hospital, Aalborg Sygehus, AARHUS, Denmark

P038 Cesarean Section and Maternal Complications
Nanneli Pallasmaa1, Ulla Ekblad1, Ansa Aitokallio-Tallberg2, Jukka Uotila3, Tytti Raudaskoski1, Veli-Matti Ulander4
1Turku University Central Hospital, TURKU, Finland
2Helsinki University Central Hospital, HELSINKI, Finland
3Tampere University Hospital, TAMPERE, Finland
4Oulu University Hospital, OULU, Finland

P039 Complications of caesarean section
Heiðdis Valgeirsdóttir, Hildur Harðardóttir, Ragnheiður Bjarnadóttir
Landspítali University Hospital, REYKJAVÍK, Iceland

P040 Mode of delivery in UK mothers with HIV
Britt Claussen, Stella Sebuwufu
Mayday University Hospital, CROYDON, United Kingdom

P041 Does TachoSil® improve the healing of the myometrium after caesarean section?
Gitte Bennich, Lene B Paulsen, Pernille Nørgaard, Martin Rudnicki
Roskilde University Hospital, ROSKILDE, Denmark

P042 Cesarean section and risk for pelvic organ prolapse – an epidemiologic register study and a metaanalysis
Christina Larsson
Karolinska Institute, STOCKHOLM, Sweden

P043 Effect of cimetidine on the transfer of metformin in dually perfused human placenta
Kristina Tertti1, Ulla Ekblad1, Tuija Heikkinen1, Melissa Rahi1, Tapani Rönnemaa1, Kari Laine2
1Turku University Central Hospital, TURKU, Finland
2University of Turku, TURKU, Finland

P044 Placental infarcts in preeclamptic, gestational hypertensive, Intrauterine Growth Retardation (IUGR) and normotensive pregnancies
Anita Sylvest Andersen1, Ulla Engel2, Anne Wahlín3, Helle Christina Sørensen3, Jørgen G Berthelsen4, Michael Rud Lassen1, Thomas Bergholt4
1Hillerød Hospital, HILLERØD, Denmark
2Department of Pathology, Hospital Hospital, HILLERØD, Denmark
3Department of Gynecology and Obstetrics, Glostrup Hospital, GLOSTRUP, Denmark
4Department of Gynecology and Obstetrics, Hillerød Hospital, HILLERØD, Denmark
5Clinical Trial Unit, Hørsholm Hospital, HØRSHOLM, Denmark

P045 Histopathological examination of PCOS placentas – metformin or placebo in pregnancy
Solhild Stridsklev, Eszter Vanky, Sven Carlsten, Christina Vogt Isaksen
NTNU/ St. Olavs Hospital, TRONDHEIM, Norway

P046 Maternal risk factors for fetal growth restriction (FGR) in Latvia
Natalija Vedmedovska1, Dace Ezerina2, Dace Rezeberga1, Irina Jermakova1
1Rīga Stradiņš University, RĪGA, Latvia
2Rīga Maternity Hospital, RĪGA, Latvia

P047 Respiratory dysfunction in infants born by elective cesarean section without labor
Snorri Donaldsson, Hildur Hardardottir, Hóður Pórkelsson, Atlí Dagbjartsson, Hóður Bergsteinsson, Ásgeir Haraldsson
Landspítali University Hospital, REYKJAVÍK, Iceland
P048 Oxygen transport to the fetus during normal vaginal delivery and during elective Cesarean section
Thordur Thorkelsson¹, Anton Bjarnason¹, Hildur Hardardottir², Adalbjorn Thorsteinsson¹, Asgeir Haraldsson¹, Atli Dagbjartsson¹
¹Children's Hospital Iceland, REYKJAVIK, Iceland
²National University Hospital Iceland, Dpt. of obstetrics and gynecology, REYKJAVIK, Iceland

P049 Birth asphyxia and hypoxic ischemic encephalopathy, incidence and obstetric risk factors
Kolbrún Pálsdóttir, Hildur Hardardottir, Þórdur Þórkelsson, Atli Dagbjartsson
Landspitali University Hospital, REYKJAVIK, Iceland

P050 Birth asphyxia, neonatal risk factors for hypoxic ischemic encephalopathy
Kolbrún Pálsdóttir, Hildur Hardardottir, Þórdur Þórkelsson, Atli Dagbjartsson
Landspitali University Hospital, REYKJAVIK, Iceland

P051 Assessment of perinatal outcome – analysis of 7 years of STAN usage in normal pregnancies
Håkan Norén, Ann Carlsson
Sahlgrenska university hospital, MÖLNDAL, Sweden

P052 Low umbilical artery pH level at birth associates with the development of asthma among 5–6 year old children
Leea Keski-Nisula¹, Baizhuang Xu², Tuula Putus², Juha Pekkanen²
¹Kuopio University Hospital, KUOPIO, Finland
²Unit of Environmental Epidemiology, National Public Health Institute, KUOPIO, Finland

P053 Risks associated with extremely large babies
Harpa Vidarsdottir, Reynir Tomas Geirsson, Atli Dagbjartsson, Hildur Hardardottir, Unnur Valdimarsdottir
¹Landspitali University Hospital, REYKJAVIK, Iceland
²University of Iceland, REYKJAVIK, Iceland
³Landspitali University Hospital, Dept. of Pediatrics, REYKJAVIK, Iceland

P054 Pregnancy exposure to venlafaxine, preterm delivery and Apgar score
Lars Henning Pedersen¹, Tine Brink Henriksen², Jørn Olsen³
¹University of Aarhus, Dept. of Epidemiology, AARHUS C, Danmark
²Perinatal Epidemiology Research Unit, Dept. of Pediatrics, Aarhus University, AARHUS, Danmark
³UCLA School of Public Health, Dept. of Epidemiology, LOS ANGELES, CALIFORNIA, USA

P055 PCOS and breast feeding
Eszter Vanky
Inst of laboratory medicine, childrens and womens health, TRONDHEIM, Norge

P056 Maternal androgen levels associate negatively with breastfeeding
Sven Magnus Carlsten¹, Geir Jacobsen¹, Eszter Vanky¹
¹Inst. for laboratory medicine, childrens and womens health, TRONDHEIM, Norge
²Department of Public Health and General Practice, TRONDHEIM, Norge

P057 Maternal mortality and near-miss morbidity in metropolitan La Paz, Bolivia
Mattias Rööst¹, Jerker Liljestrand², Birgitta Essén¹
¹International Maternal and Child Health, IMCH, Uppsala University, UPSALA, Sweden
²Department of Health Sciences/Division of Social Medicine and Global Health, MALMÖ, Sverige

P058 Physical and mental handicaps among women examined at center for victims of sexual assault (CFVSA) in copenhagen
Malene Hilden, Katrine Sidenius
Rigshospitalet, COPENHAGEN, Denmark

P059 TNF-a polymorphism and pathogenesis of Chlamydia trachomatis associated infertility
Jorma Paavonen¹, H Öhman², A Tiitinen³, M Halttunen¹, M Lehtinen¹, J Paavonen¹, H-M Surcel¹
¹Helsinki University Central Hospital, HELSINKI, Finland
²National Public Health Institute, OULU, Finland
³University of Tampere, School of Public Health, TAMPERE, Finland
P060 Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study
Per-Göran Larsson1, Babill Stray-Pedersen2, Keld Rytting1, Stig Larsen3, Preben Borrelli4
1Kvinnokliniken, SKÖVDE, Sweden
2Rikshospitalet, OSLO, Norge
3Farmaservice, KOPENHAMN, Danmark
4Scolle of veterinary Science, Ulevål, OSLO, Norge
5Bifodan A/S, HUNDESTAD, Denmark

P061 The Effect of Endometrial Thickness on In vitro fertilization (IVF)-Embryo Transfer/Intracytoplasmic Sperm Injection (ICSI) Outcome
Jude Okohue1, Sunday Onuh2, Sunday Shaibu3, Peter Ebeigbe3, Eugene Okpere4
1Prime medical consultants, PORTHARCOURT, RIVERS STATE, Nigeria
2Nordica fertility centre@ Nisa premier hospital, ABUJA, Nigeria
3Department of obstetrigynaecol, college of medicine, Delta state university, DELTA, Nigeria
4Department of obstetrigynaecol, University of Benin Teaching Hospital, EDO, Nigeria

P062 Intrauterine polyps and their influence on infertility
Ditte Josefine Roer1, Helle Vibeke Clausen1, Søren Stampe Sørensen2
1Herlev University hospital, HERLEV, Denmark
2Glostrup University Hospital, GLOSTRUP, Denmark

P063 Biochemical and morphological changes in the uterine cervix after pre-treatment with isosorbide mononitratre and misoprostol
Nina Vukas Radulovic, Erling Ekerhovd, Anders Norström
Sahlgrenska Universitetssjukhus, GÖTEBORG, Sverige

P064 The advantage of daily symptom ratings for the diagnosis of menstrual cycle linked conditions
Sigrid Nyberg1, Stefan Hammarbäck2, Marie Bixo3, Inger Sundström-Poromaa2, Torbjörn Bäckström2
1Norrlands Universitetssjukhus, UMEÅ, Sverige
2Inst Clinical Science, obstetrics and gynecology, UMEÅ, Sweden
3Inst of Women’s and Children’s Health, UPPSALA, Sweden

P065 Association of Interleukin-10 Promoter Polymorphism with Endometriosis
Mads Riiskjær1, Kaspar Nielsen2, Rudi Steffensen3, Christian Erikstrup3, Axel Forman1, Christina Kruse3
1Aarhus University Hospital, Skejby, AARHUS N, Denmark
2Aarhus University Hospital, AALBORG, Denmark

P066 Decreased blood flow in left medial prefrontal and right striatal areas correlates to increased self-rated fatigue in women with premenstrual dysphoria
Olle Eriksson1, Tord Naessén2, Anders Wall3, Gunnar Blomqvist4, Bengt Långström5, Anton Forsberg6, Ina Marteinsdottir7, Hans Ågren8, Per Hartvig9
1Women’s and Children’s health/ObGyn, UPPSALA, Sweden
2Department of Women’s and Children’s health, UPPSALA, Sweden
3Uppsala Imanet, GE Healthcare, UPPSALA, Sweden
4Department of Neurology, Karolinska Institutet, STOCKHOLM, Sweden
5Department of Neuroscience, Section of Psychiatry, Akademiska sjukhuset, UPPSALA, Sweden
6Department of Clinical Neuroscience, Section of Psychiatry at Huddinge, K.I., STOCKHOLM, Sweden
7Hospital Pharmacy, AKADEMISKA SJUKHUSET, Sweden

P067 Difference in hormonal levels between lean and overweight women with PCOS
Thilde Sangild Villemann, Birgitta Trolle
Aarhus University Hospital Skejby, ÅRHUS V, Denmark
P068 Metabolic characteristics/features of first degree relatives of women with polycystic ovary syndrome
Assi Torvinen1, Riitta Koivunen2, Anneli Pouta3, Stephen Franks4, Hannu Martikainen5, Aini Bloigu1, Anna-Liisa Hartikainen6, M.I. McCarthy6, Aimo Ruokonen7, M-R. Järvelin8, Laure Morin-Papunen1
1Oulu University, OULU, Finland
2Family Federation of Finland, OULU, Finland
3Dept. of Public Health Science and General Practice, UNIVERSITY OF OULU, Finland
4Institute of Reproductive and Developmental Biology, Imperial College, LONDON, United Kingdom
5Dept. of Obstetrics and Gynaecology, UNIVERSITY HOSPITAL OF OULU, Finland
6Oxford Centre for Diabetes, Endocrinology and Metabolism, OXFORD, United Kingdom
7Dept. of Clinical Chemistry, UNIVERSITY HOSPITAL OF OULU, Finland
8Dept. of Epidemiology and Public Health, Imperial College, LONDON, United Kingdom

P069 The Cost-Effectiveness of estradiol 0.5 mg /norethisterone acetate 0.1 mg for Swedish Women with an Intact Uterus and Menopausal Symptoms
Ann-Sofie Brandt1, Oskar Ström2, Dorothea Koeppe-Utelli3, Vicki Munro1
1Novo Nordisk, CRAWLEY, United Kingdom
2i3 Innovus, STOCKHOLM, Sweden
3Novo Nordisk Region Europe A7S, ZURICH, Switzerland

P070 Hormone Therapy modulates ETA mRNA expression in the aorta of ovariectomized New Zealand White Rabbits
Susan Pedersen1, Lars Bo Nielsen1, Nina Gros Pedersen1, Lisbeth Nilas2, Bent Ottesen3
1Hillerød Hospital, HILLEROED, Danmark
2Dept. of Clinical Biochemistry, Copenhagen University Hospital, COPENHAGEN, Danmark
3The Juliane Marie Centre, Copenhagen University Hospital, COPENHAGEN, Danmark

P071 A longitudinal study of contraception in the same women, born in 1962, followed over a quarter of a century
Ingela Lindh, Agneta Andersson-Ellström, Febe Blohm, Ian Milsom
Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, GÖTEBORG, Sweden

P072 Age, parity, history of abortion and contraceptive choices affect the risk of repeated abortion
Oskari Heikinheimo1, Mika Gissler2, Satu Suhonen3
1Univ of Helsinki, HELSINKI, Finland
2National Research and Development Centre for Welfare and Health, HELSINKI, Finland
3Dept Ob&Gyn, Univ of Helsinki, HELSINKI, Finland

P073 Satisfaction with contraceptive services and contraceptive behaviour in Estonia, Russia and Finland
Made Laanperë1, Tatiana Dubikaytis2, Minna Nikula3, Kai Part4, Kai Haldre5, Elina Hemminki6, Helle Karro1
1University of Tartu, TARTU, Estonia
2St. Petersburg Medical Academy of Postgraduate Studies, ST. PETERSBURG, Russian Federation
3National Research and Development Centre for Welfare and Health, HELSINKI, Finland

P074 Is the use of reliable contraceptive methods associated with contraceptive service type?
Kai Part1, Kaja Rahu2, Made Laanperë3, Kai Haldre1, Mati Rahu2, Helle Karro1
1University of Tartu, TARTU, Estonia
2National Institute for Health Development, TALLINN, Estonia

P075 Prevalence of psychiatric disorders and premenstrual symptoms in patients with ongoing or prior experience of adverse mood during treatment with combined oral contraceptives
Birgitta Segeblad
Uppsala University, UPPSALA, Sweden

P076 Does smoking affect the result of treatment for urinary incontinence?
Rikke Guldberg1, Torsten Sorensen2
1Kolding Hospital, FREDERICIA, Danmark
2Kolding hospital, KOLDING, Danmark
P077 Pelvic floor muscle training in the prevention and treatment of urinary incontinence in women – what is the evidence? A systematic review
Sørøen Brøstøm, Gunnar Lose
Glostrup Hospital, GLOSTRUP, Denmark

P078 Nocturia in relation to sleep quality in an unselected population of women and men aged 60–80 years in Denmark
Mette Hornum Bing, Poul Jennum, Lars Aling Møller, Svend Mortensen, Gunnar Lose
Glostrup Hospital, GLOSTRUP, Denmark

P079 Risk factors for complications with the TVT-procedure
Kjell Schedvins1, Elsa Ryde-Blomqvist1
1Karolinska University Hospital, STOCKHOLM, Sverige
2PSR, STOCKHOLM, Sweden

P080 The effect of hysterectomy or LNG-IUS on wellbeing – A 5-year randomised controlled trial
Satu Heliövaara-Peippo1, Karoliina Halmesmäki1, Ritva Hurskainen2, Juha Teperi3, Seija Grenman4, Aarre Kivelä5, Erkki Kujansuu6, Marjo Tuppurainen7, Merja Yliskoski8, Sirku Vuorma9, Jorma Paavonen9
1University of Helsinki, HELSINKI, Finland
2Department of Obstetrics and Gynecology, University of Helsinki, HELSINKI, Finland
3Health Services Research Unit, STAKES, HELSINKI, Finland
4Department of Obstetrics and Gynecology, University of Turku, TURKU, Finland
5Department of Obstetrics and Gynecology, University of Oulu, OULU, Finland
6Department of Obstetrics and Gynecology, University of Tampere, TAMPERE, Finland
7Department of Obstetrics and Gynecology, University of Kuopio, KUOPIO, Finland
8Central Hospital of Central Finland, JYVÄSKYLÄ, Finland
9National Public Health Institute, HELSINKI, Finland

P081 Introduction of bipolar hysteroscopic transcervical endometrial resection (TCER) in a rural hospital in Iceland
Vilhjalmur Kr. Andrésson1, Lýður Ólafsson1, Olav Istre1
1Akranes hospital and general healthcare center, AKRANES, Iceland
2Ullevål University Hospital, OSLO, Norway

P082 Intravenous Tranexamic Acid And Total Abdominal Hysterectomy: A Prospective Randomized Study
Rikke Gulberg1, Andersen Bent2
1Kolding Hospital, FREDERICIA, Danmark
2Kolding hospital, KOLDING, Danmark

P083 The treatment of Bartholin’s cyst or abscess with silver nitrate
Pinar Bor, Niels Ole Knoblach, Inger Stornes
Randers Hospital, RANDERS, Danmark

P084 Long-term outcome following radical surgery for rectovaginal endometriosis (RVE)
Satu Tarjanne1, Jan Sjöberg, Oskari Heikinheimo
Helsinki University Hospital, HELSINKI, Finland

P085 Posterior intravaginal slingplasty sling versus unilateral sacrospinous ligament fixation in treatment of severe vaginal vault prolapse
Virva Nyyssönen1, Anne Talvensaari-Mattila2, Markku Santala2
1North Carelian Central Hospital, JOENSUU, Finland
2Oulu University Hospital, OULU, Finland

P086 The Essure transcervical sterilisation procedure, a review of case series
Marie-Louise Saaby, Søren Stampe Sørensen
Glostrup Hospital, GLOSTRUP, Danmark

P087 Uterine vascular malformation after elective termination of pregnancy. A case report
Maia-Riitta Oröndén, Petri Sipola, Anu Ruuskanen, Hannu Manninen
Kuopio University Hospital, KUOPIO, Finland
P088 Medical abortion in Iceland - experience from the first 246 treatments
Ágúst Ingi Ágústsson, Jens A. Guðmundsson, Kristín Jónsdóttir
Landspitali University Hospital, REYKJAVIK, Iceland

P089 Cytology quality in the national cervical screening program in Slovenia
Leon Meglic, Andrej Mozina, Stelio Rakar
University Clinical Center, LJUBLJANA, Slovenia

P090 Human Papillomavirus persistence after treatment for cervical dysplasia with conization and laser vapourisation
Lennart Kjellberg
University of Umeå, UMEÅ, Sweden

P091 HPV- testing of women aged 30 and above with the diagnosis ASC-US/LSIL cervical cytology in the Copenhagen population screening programme for cervical cancer
Benny Kirschner1, Kåre Simonsen2, Jette Junge2
1Herlev Hospital, COPENHAGEN, Danmark
2Dep. of pathology, Hvidovre Hospital, COPENHAGEN, Denmark

P092 Evaluation of tampon as a suitable self sampling device for detection of HPV mRNA from cervical cells – a preliminary report
Hanne Skomedal1, Runi Rogers1, Greta Dreyer1
1NorChip AS, KLOKKARSTUA, Norge
2University of Pretoria, PRETORIA, South Africa

P093 Increased MMP-2, MMP-9 and TIMP-2 expression is associated with progression from VIN to invasive vulvar carcinoma
Anne Talvensaari-Mattila, Milla Määttä, Ylermi Soini, Taina Turpeenniemi-Hujanen, Markku Santala
Oulu University, OULU, Finland

P094 ‘Complications after extensive surgery for epithelial ovarian cancer FIGO stage IIIC and IV in a Nordic Centre. Experiences from the first nine months’
Kirsten Jochumsen, Ole Mogensen
Odense University Hospital, ODENSE C, Denmark

P095 GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors
Mikko Anttonen1, Antti Kyrölähti1, Leila Unkila-Kallio1, Ralf Butzow1, Arto Leminen1, Ilpo Huhtaniemi1, Markku Heikinheimo1
1Children’s Hospital and Program for Women’s Health, University of Helsinki, HELSINKI, Finland
2Department of Obstetrics and Gynecology, Helsinki University Central Hospital, HELSINKI, Finland
3Department of Pathology, Helsinki University Central Hospital, HELSINKI, Finland

P096 Vascular endothelial growth factor in granulosa cell tumors
Anniina Färkkilä1, Antti Kyrölähti1, Leila Unkila-Kallio1, Ralf Butzow1, Markku Heikinheimo1, Mikko Anttonen1
1Children’s Hospital and Program for Women’s Health, University of Helsinki, HELSINKI, Finland
2Department of Obstetrics and Gynecology, Helsinki University Central Hospital, HELSINKI, Finland
3Department of Pathology, Helsinki University Central Hospital, HELSINKI, Finland

P097 The tumor suppressors p53, p27 and p21, their relationship and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
Ingiridur Skörndsdottr1, Katarina Lindborg1, Bengt Sorbe1, Tomas Seidal1
1Department of Obstetrics and Gynecology, Akadem, UPPSALA, Sweden
2Department of Gynecological Oncology, Örebro University Hospital, Örebro, ÖREBRO, Sverige
3Department of Pathology, Halmstad Medical Center Hospital, Halmstad, Sweden
P098 Simulation based Team Training as a Tool to Improve Patient Safety and Communication Skills
Marlene Mohr¹, Doris Oestergaard², Morten Lebech¹, Henriette Hintz³, Nini Vallebo², Anette Lewkowitch², Berit Woetmann Petersen¹, Kurt Nielsen⁵
¹University hospital in Herlev, Copenhagen, HERLEV, Denmark
²Danish institute for Medical Simulation, HERLEV, COPENHAGEN, Denmark
³Department of Gynaecology and Obstetrics, HERLEV, Denmark
⁴Department of Gynaecology and Obstetrics, Rigshospitalet, COPENHAGEN, Denmark
⁵Department of Anaesthesiology, ROSKILDE, Denmark

P099 Retention of Skills in Procedural Laparoscopic Virtual Reality Simulator Training
Mathilde Maagaard¹, Jette Led Soerensen¹, Torur Dalsgaard², Bent Ottesen¹, Teodor P Grantcharov³, Christian Rifbjerg Larsen¹
¹Rigshospitalet, COPENHAGEN Ø, Denmark
²Rigshospitalet, COPENHAGEN, Denmark
³St Michael’s hospital, TORONTO, Canada

P100 An Observational Crossover Comparison of Specialist Training in Obstetrics and Gynaecology in Great Britain and Denmark
Morten Beck Sorensen
West Middlesex University Hospital, LONDON, United Kingdom
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15–09:00</td>
<td>IS-029 Plenary lecture: Preeclampsia</td>
<td>Main Hall</td>
</tr>
<tr>
<td></td>
<td>Chair: Alexander Smárason</td>
<td></td>
</tr>
<tr>
<td></td>
<td>James Walker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The University of Leeds, LEEDS, UK</td>
<td></td>
</tr>
<tr>
<td>09:00–10:30</td>
<td>Skills training, simulation and assessment II</td>
<td>Main Hall</td>
</tr>
<tr>
<td></td>
<td>Chairs: Juha Mäkinen and Bent Ottesen</td>
<td></td>
</tr>
<tr>
<td>09:00–09:25</td>
<td>IS-030 Organization of training and integration of skill training in the curriculum on a local, regional and national level</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guylaine Lefebvre</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Society of Obstetricians and Gynecologists of Canada, TORONTO, Canada</td>
<td></td>
</tr>
<tr>
<td>09:25–09:50</td>
<td>IS-031 Simulator training and assessment in laparoscopic gynaecology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Christian Rifbjerg Larsen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rigshospitalet, COPENHAGEN, Denmark</td>
<td></td>
</tr>
<tr>
<td>09:50–10:15</td>
<td>IS-032 The surgical curriculum; an evidence-based approach</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Teodor Grantcharov</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Toronto, St. Michael’s Hospital, TORONTO, Canada</td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:00–10:30</td>
<td>Rare serious events in obstetrics</td>
<td>Hall 1</td>
</tr>
<tr>
<td></td>
<td>Chairs: Lone Krebs and NN</td>
<td></td>
</tr>
<tr>
<td>09:00–09:25</td>
<td>IS-033 Eclampsia and Acute Fatty Liver of Pregnancy: The study of rare disorders of pregnancy using the UK Obstetric Surveillance System (UKOSS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marian Knight</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Perinatal Epidemiology Unit, OXFORD, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>09:25–09:45</td>
<td>IS-034 European Obstetric Survey System, EUROSS – The Nordic perspective</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jens Langhoff-Roos</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rigshospitalet, COPENHAGEN Ø, Danmark</td>
<td></td>
</tr>
<tr>
<td>09:45–10:10</td>
<td>IS-035 Experiences from a center for pregnant women with heart disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marianne Johansen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Juliane Marie Centre for Children, Women and Reproduction Copenhagen Univers, COPENHAGEN Ø, Denmark</td>
<td></td>
</tr>
<tr>
<td>10:10–10:30</td>
<td>IS-036 Hysterectomy for life-threatening peripartum haemorrhage: Study of a ‘near-miss’ event</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marian Knight</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Perinatal Epidemiology Unit, OXFORD, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>09:00–10:30</td>
<td>Oncology. Free communications III</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td>Chairs: Anna Salvardsdottir and Seija Grénman</td>
<td></td>
</tr>
<tr>
<td>09:00–09:10</td>
<td>ON1 Breast cancer risk in postmenopausal women using estrogen-progestin therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heli Lytinen¹, Eero Pukkala², Olavi Ylikorkala¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>¹Helsinki University Hospital, HELSINKI, Finland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>²Finnish Cancer Institute, HELSINKI, Finland</td>
<td></td>
</tr>
</tbody>
</table>
**ON2 HPV genotype distribution and E6/E7 mRNA expression in Norwegian women with cervical neoplasia**
Katrine Dønvold Sjøborg, Ameli Trope, Tormod Eriksen, Vigdis Lauvra, Martin Steinbakk, Morten Jacobsen, Agnes Kathrine Lie, Anne Eskild
1. Østfold Hospital Trust, Fredrikstad, Norway
2. Akershus University Hospital, Lørenskog, Norway
3. Cancer Registry of Norway, Oslo, Norway

**ON3 Framingham risk score and the metabolic syndrome in epithelial ovarian cancer survivors: a controlled observational study**
Astrid Helene Liavaag, Serena Tonstad, Are H Pripp, Claes Trope, Anne Dørum
1. Sørlandets Sykehus, Arendal, Norway
2. Department of Internal Medicine, Ullevål University Hospital, University of Oslo, Oslo, Norway
3. Biostatistics Unit, Research Services Department, Rikshospitalet, Oslo, Norway
4. Department of Gynecological Oncology The Norwegian Radiumhospital, Oslo, Norway

**ON4 Gynecological cancer and urinary incontinence**
Finn Egil Skjeldestad, Bjørn Hagen
Institute of Laboratory Medicine, Children- and Womens' Diseases, Trondheim, Norway

**ON5 Treatment for cervical intraepithelial neoplasia and preterm birth**
Maija Jakobsson, Mika Gissler, Jorma Paavonen, Anna-Maja Tapper
1. Helsinki University Hospital, Helsinki, Finland
2. STAKES National Research and Development Centre for Welfare and Health, Helsinki, Finland

**ON6 Human Papillomavirus infection is associated with increased cervical nitric oxide release in the human uterine cervix**
Päivi Rahkola, Tomi Mikkola, Pekka Nieminen, Olavi Ylikorkala, Mervi Väisänen-Tommiska
Helsinki University Central Hospital, Finland, Helsinki, Finland

---

**Medical abortion**

**IS-037 Cervical ripening**
Helena Hertzen von World Health Organization, Geneva, Switzerland

**IS-038 Contraception after abortion**
Oskari Heikinheimo Helsinki University Hospital, Helsinki, Finland

**IS-039 Medical abortion in late first trimester (9–12 w)**
Ole Erik Iversen Haukeland Universitetssykehus, Bergen, Norway

**IS-040 Medical abortion in very early pregnancy**
Christian Fiala Gynmed Clinic, Vienna, Austria

**IS-041 Home-use of misoprostol in medical abortion**
Kristina Gemzell Danielsson Karolinska Institutet, Stockholm, Sweden

**IS-042 Is there a ‘window of opportunity’**
Göran Samsoe Lund University Hospital, Lund, Sweden

---

**Hormone treatment in the climacteric – options for today and tomorrow**

**IS-042 Is there a ‘window of opportunity’**
Göran Samsoe

---

NFOG 2008
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25–11:50</td>
<td>IS-043 Alternative treatment from an evidence based perspective</td>
<td>Mette Haase Moen</td>
<td>St Olavs University Hospital, TRONDHEIM, Norway</td>
</tr>
<tr>
<td>11:50–12:15</td>
<td>IS-044 Guidelines for HT from an International perspective</td>
<td>Sven O. Skouby</td>
<td>University of Copenhagen, COPENHAGEN, Denmark</td>
</tr>
<tr>
<td>12:15–12:30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Severe maternal hemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Birgit Bødker and Knud Hordnes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:45</td>
<td>IS-045 Pathophysiology of severe PPH and general management</td>
<td>Jouni Ahonen</td>
<td>Maternity Hospital, Helsinki University Hospital, HELSINKI, Finland</td>
</tr>
<tr>
<td>11:45–12:05</td>
<td>IS-046 Placenta Accreta</td>
<td>Adam Borgida</td>
<td>Hartford Hospital, CONNECTICUT, USA</td>
</tr>
<tr>
<td>12:05–12:30</td>
<td>IS-047 New methods in treating severe postpartum hemorrhage (PPH)</td>
<td>Kjell Salvesen</td>
<td>National Center for Fetal Medicine, TRONDHEIM, Norway</td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Fetal surveillance. Free communications IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Jens Langhoff-Roos and NN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:10</td>
<td>FS1 Acidaemia at birth related to management of the last two hours of labour</td>
<td>Maria Jonsson1, Solveig Nordén Lindeberg1, Ingrid Östlund1, Ulf Hanson1</td>
<td>Department of Women’s and Children’s Health Uppsala University Uppsala, UPPSALA, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department of Obstetrics and Gynecology, ÖREBRO, Sweden</td>
<td></td>
</tr>
<tr>
<td>11:10–11:20</td>
<td>FS2 Evaluation and impact of CTG training programmes</td>
<td>Caroline Pehrson1, Jette Led Soerenson1, Isis Amer-Wåhlin1</td>
<td>Sygehus Syd Næstved, NÆSTVED, Danmark</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obstetric Department and Juliane Marie Centre, Rigshospitalet, COPENHAGEN, Danmark</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department of Women and Child Health, Karolinska University Hospital, STOCKHOLM, Sverige</td>
<td></td>
</tr>
<tr>
<td>11:20–11:30</td>
<td>FS3 Neonatal resuscitation of asphyctic infants due to obstetrical malpractice in conjunction with labour in Sweden 1990–2005</td>
<td>Sophie Berglund1, Mikael Norman1, Charlotta Grunewald1, Hans Pettersson1, Sven Cnattingius1</td>
<td>Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institut, STOCKHOLM, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department for Clinical Science, Intervention and Technology,, STOCKHOLM, Sweden</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department of Medical Epidemiology and Biostatistics,, STOCKHOLM, Sweden</td>
<td></td>
</tr>
<tr>
<td>11:30–11:40</td>
<td>FS4 Obstetricians’ choice of delivery method in ambiguous cases: Is it influenced by risk attitude?</td>
<td>Dorthe Fuglenes1, Pål Øian2, Ivar Sønbø Kristiansen3</td>
<td>University of Oslo, OSLO, Norway</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department of Obstetrics and Gynecology, University Hospital of North Norway, TROMSØ, Norway</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Institute of Health Management and Health Economics, University of Oslo, OSLO, Norway</td>
<td></td>
</tr>
<tr>
<td>11:40–11:50</td>
<td>FS5 Implementation of new intra partum fetal monitoring in a Danish Hospital: Impact on the rate of operative delivery and neonatal outcome</td>
<td>Isis Amer-Wåhlin1, Heidi Fosgraun Sharif2, Kristine Sylvan Andersen2, Thomas Bergholt3, Morten Hedegaard4</td>
<td>Karolinska Institute, SOLNA, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obstetric Clinic, Juliane Marie Center,Rigshospitalet, Copenhagen University, COPENHAGEN, Denmark</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Department of Obstetrics and Gynecology, Hillerod Hospital, Copenhagen University, COPENHAGEN, Denmark</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Juliane Marie Center, Rigshospitalet, COPENHAGEN, Denmark</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Presenters</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11:50–12:00</td>
<td><strong>FS6 Clinical experience with CTG and ST analysis of the fetal electrocardiogram – low cord metabolic acidosis rate at a tertiary care centre</strong>&lt;br&gt;Jørg Kessler, G Midbøe, T Hahn, F Macsali, E Wik, S Albrechtsen  &lt;br&gt;<strong>Haukeland University Hospital, BERGEN, Norway</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:10</td>
<td><strong>FS7 ST analysis and prevention of hypoxia – the Turku experience</strong>&lt;br&gt;Susanna Timonen  &lt;br&gt;<strong>Turku University Hospital, TURKU, Finland</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10–12:20</td>
<td><strong>FS8 Adverse outcome in relation to use of STAN</strong>&lt;br&gt;Isis Amer-Wåhlin¹, Branka Yli², Håkan Norén¹  &lt;br&gt;¹Karolinska Institute, SOLNA, Sweden&lt;br&gt;²Department of Obstetrics and Gynaecology, Rikshospitalet, University of Oslo, OLSO, Norway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20–12:30</td>
<td><strong>FS9 Fetal monitoring with CTG in combination with ST analysis vs. CTG alone – a cost-effectiveness analysis</strong>&lt;br&gt;Emelie Heintz¹, Thor-Henrik Brodtkorb¹, Nina Nelson², Lars-Åke Levin¹  &lt;br&gt;¹Center for Medical Technology Assessment, LINKÖPING, Sweden&lt;br&gt;²Division of Paediatrics, Linköping University Hospital, LINKÖPING, Sweden</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Contraception Hall 3

**Chairs: Eilv Johansson and Runa Aabo**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00–11:20</td>
<td><strong>IS-048 The changing panorama of contraceptive use in the Nordic countries</strong>&lt;br&gt;Ian Milsom&lt;br&gt;Institute of Clinical Sciences, Sahlgrenska Academy, Göteborg University, GÖTEBORG, Sweden</td>
<td></td>
</tr>
<tr>
<td>11:20–11:40</td>
<td><strong>IS-049 The use of LNG-IUS in nulliparous women</strong>&lt;br&gt;Satu Suhonen&lt;br&gt;Helsinki City, HELSINKI, Finland</td>
<td></td>
</tr>
<tr>
<td>11:40–12:00</td>
<td><strong>IS-050 Menstrual cycle suppression. An endocrine treatment and a modern solution to a modern problem</strong>&lt;br&gt;Leslie Miller&lt;br&gt;University of Washington, SEATTLE, USA</td>
<td></td>
</tr>
<tr>
<td>12:00–12:20</td>
<td><strong>IS-051 Hormonal contraception and risk of venous thromboembolism. Dose reduction matters</strong>&lt;br&gt;Øjvind Lidegaard&lt;br&gt;Rigshospitalet, COPENHAGEN Ø, Danmark</td>
<td></td>
</tr>
<tr>
<td>12:20–12:30</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Lunch symposium – sponsored by Sanofi Pasteur MSD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30–12:35</td>
<td><strong>Opening Introduction</strong>&lt;br&gt;Assoc. Professor Cecilia Young</td>
<td></td>
</tr>
<tr>
<td>12:35–12:55</td>
<td><strong>GARDASIL® (Quadrivalent HPV Vaccine)</strong>&lt;br&gt;An Update with 4 years Clinical Efficacy Data&lt;br&gt;Nubia Munoz – M.D. MPH</td>
<td></td>
</tr>
<tr>
<td>12:55–13:05</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>13:05–13:25</td>
<td><strong>Benefits of GARDASIL®</strong>&lt;br&gt;– On other HPV types&lt;br&gt;– In women above 25 years&lt;br&gt;Professor Ole Erik Iversen M.D.</td>
<td></td>
</tr>
<tr>
<td>13:25</td>
<td><strong>Discussion and Closure</strong></td>
<td></td>
</tr>
</tbody>
</table>
12:30–14:00 Lunch symposium – sponsored by Renapharma
  Postpartum anemia – what is the optimal treatment? Hall 2

  Erythropoiesis during pregnancy
  Ivor Cavill, CARDIFF, United Kingdom

  IV iron vs oral iron
  Results of the Norwegian Multicenter Study
  Stian Westad, LILLEHAMMER, Norway

  IV ferric carboxymaltose
  Results of the American Multicenter Study
  Tom Goodnough, STANFORD, CAL, USA

  Blood transfusion? No, thank you!
  Ivor Cavill, CARDIFF, United Kingdom

12:30–14:00 General Assembly Hall 4
  Chair: Peter Hornnes

14:00–14:45 Plenary: Should we discontinue public funding of assisted reproduction? Main Hall
  Chair: Helle Meinertz

  IS-052 Why are European laws on reproduction so similar?
  Paul Devroey
  Centre for Reproductive Medicine, BRUSSELS, Belgium

  IS-053 It is a mistake to limit public funding of assisted reproduction
  Johannes Evers
  Maastricht University Medical Center, MAASTRICHT, Nederland

14:45–16:15 Genetic medicine Main Hall
  Chairs: Hildur Harðardóttir and Thue Bryndorf

  14:45–15:15 IS-054 Genetic counselling: psychosocial issues and decision making
  Heather Skirton
  University of Plymouth, TAUNTON, United Kingdom

  15:15–15:45 IS-055 Heritable gynecological cancer
  Anne-Marie Gerdes
  Odense University Hospital, ODENSE C, Danmark

  15:45–16:15 IS-056 Combined risk assessment for fetal aneuploidy with nuchal translucency and biochemical markers. The Danish experience, before and after the guidelines from Sundhedsstyrelsen
  Ann Tabor
  Copenhagen University Hospital, Rigshospitalet, COPENHAGEN Ø, Danmark

14:45–16:15 Fear of childbirth – what is it about and what can we do? Hall 1
  Chairs: Charlotta Grunewald and Jukka Uotila

  14:45–15:05 IS-057 Depression and anxiety during pregnancy – prevalence and obstetric outcome
  Liselott Andersson
  Sunderby hospital, LULEÅ, Sweden

  15:05–15:25 IS-058 Violence against women may influence childbirth
  Berit Schei
  NTNU, TRONDHEIM, Norge
15:25–15:45  **IS-059 Fear of childbirth and the wish for a caesarean**  
Elsa Lena Ryding  
Karolinska University Hospital, STOCKHOLM, Sweden

15:45–16:05  **IS-060 Fear of childbirth can be treated and cesarean section avoided**  
Terhi Saisto  
Helsinki Univeristy Central Hospital, HUS (HELSINKI), Finland

16:05–16:15  Discussion

14:45–16:15  **Symposium – sponsored by Bayer Schering Pharma**  
New research: Important data for counseling your OC patients

**Hall 2**

Bayer Schering Pharma: Taking a leading role in woman’s health research  
Chair: Maureen Cronin

**EURAS: The largest European active surveillance study on the safety and efficacy of OC use**  
Juergen Dinger, Germany

**Health Authority representative:**  
Steinar Madsen, Norway

**New major studies on the protective effect of OC use on ovarian and endometrial cancer**  
Ian Milsom, Sweden

**Putting the new data into perspective for your OC patients**  
Maureen Cronin, (Bayer Schering Pharma), Germany

14:45–16:25  **Presentation of theses**  
**Hall 3**

**Chairs:** Lars-Åke Mattsson and Knut Hordnes

14:45–15:05  **IS-061 Diet and lifestyle of women of childbearing age – Impact of cod liver oil consumption on maternal health, birth outcome and breast milk composition and associations between diet, lifestyle and weight gain in pregnancy**  
Anna S Olafsdottir  
Iceland University of Education, REYKJAVIK, Iceland

15:05–15:25  **IS-062 Primary fallopian tube carcinoma: occurrence, risk and prognostic factors**  
Annika Riska  
Helsinki University Hospital, HELSINKI, Finland

15:25–15:45  **IS-063 Biochemical and Epidemiological Studies of Early-Onset and Late-Onset. Pre-Eclampsia**  
Anna-Karin Wikström  
Uppsala University, Sweden

15:45–16:05  **IS-064 Total versus subtotal hysterectomy for benign uterine diseases?**  
Helga Gimbel  
Hillerøed Hospital, HILLERØD, Denmark

16:05–16:25  **IS-065 Portal and umbilical venous distribution in the human fetus**  
Jørg Kessler  
Haukeland University Hospital, BERGEN, Norway

16:15–16:45  Coffee Break / Exhibition

16:45–18:00  **Genetic medicine (cont’d)**  
**Main Hall**

**Chairs:** Hildur Harðardóttir and Thue Bryndorf

16:45–17:15  **IS-066 Prenatal screening for fetal aneuploidy in the first trimester. Nuchal translucency and biochemical markers**  
Adam Borgida  
Hartford Hospital, CONNECTICUT, USA

17:15–17:45  **IS-067 Prenatal screening for structural malformations in the first trimester**  
Hulda Hjartardóttir  
Landspitali University Hospital, REYKJAVIK, Iceland
17:45–18:00 Discussion

16:45–18:00 Preterm birth

**Chairs:** Ulf Höglund and Maija Riitta Ordén

**16:45–17:15 IS-068 Pathophysiology of preterm birth**
Henrik Hagberg  
*Perinatal Center, GÖTEBORG, Sweden*

**17:15–17:45 IS-069 Clinical management of preterm birth**
Jan Stener Jørgensen  
*Odense University Hospital, ODENSE, Denmark*

**17:45–18:00 Discussion**

16:45–18:05 Obstetrics – focus on the mother. Free communications V

**Chairs:** Alexander Smáraason and Runa Heimstad

**16:45–16:55 OM1 Non invasive observation and presentation of the propagation of uterine electrical activity during labor**
Jeremy Terrien1, Helga Medek2, Thora Steingrimsdottir1, Brynjars Karlsson1  
1Reykjavik University, REYKJAVIK, Iceland  
2Landspitali University Hospital, REYKJAVIK, Iceland

**16:55–17:05 OM2 Maintenance Therapy (MT) in Preterm Labour (PTL) – first clinical experiences**
Britta Frederiksen-Møller1, Jan Stener Jørgensen1, Andreas Herbst2  
1Odense University Hospital, ODENSE, Denmark  
2Lund University Hospital, LUND, Sweden

**17:05–17:15 OM3 Ultrasound measurements or Bishop score before induction of labor?**
Torbjørn Moe Eggbe1, Inger Økland1, Claudia Heien1, Leif Kaspar Gjessing1, Pål Romundstad2, Kjell Åsmund Salvesen2  
1Stavanger University Hospital, STAVANGER, Norway  
2Norwegian University of Science and Technology, TRONDHEIM, Norway

**17:15–17:25 OM4 Risk of Cesarean Section after Induction of Labor in Low Risk Women at Term**
Ole Bredahl Rasmussen1, Pernille Dannielskiold Lassen1, Steen Rasmussen1  
1Regionshospital Randers, RANDERS, Denmark  
2Herlev Hospital, HERLEV, Denmark

**17:25–17:35 OM5 Risk indicators for dystocia in nulliparous women**
Hanne Kjærgaard1, Jørn Olsen2, Bent Ottesen1, Anna-Karin Dykes1  
1The Juliane Marie Centre, Rigshospitalet, COPENHAGEN, Denmark  
2Department of Epidemiology, School of Public Health, University of California, LOS ANGELES, USA

**17:35–17:45 OM6 Impaired leukocyte influx and high expression of progesterone receptor (PR) and androgen receptor (AR) in postterm failed induction**
Nathalie Roos1, Ylva Vladic-Stjernholm, Lena Sahlin, Masironi Britt, Ekman-Ordeberg Gunvor  
Karolinska Institutet, STOCKHOLM, Sweden

**17:45–17:55 OM7 Postpartum perineal repair performed by midwives: a randomised trial comparing two suture techniques leaving the skin unsutured**
Sara Kindberg1, Misan Stehouwer1, Lone Hvidman1, Tine Brink Henriksen1  
1Perinatal Epidemiology Research Unit, ÅRHUS N., Denmark  
2Department of Gynaecology and Obstetrics, AARHUS N., Denmark
OM8 Maternal mortality in Denmark 2002–2006
Birgit Bødker1, Jette Led Sørensen2, Margrethe Møller2, Lone Hvidman4, Tom Weber5
1Hillerød Hospital, HILLERØD, Denmark
2Rigshospitalet University Hospital, COPENHAGEN, Denmark
3Aalborg University Hospital, AALBORG, Denmark
4Aarhus University Hospital, SKEJBY, Denmark
5Hvidovre University Hospital, COPENHAGEN, Denmark

New trends in handling male infertility

Chairs: Per Olof Janson and Helle Meinertz

IS-070 New trends in handling male infertility - Male infertility tests in the era of ICSI. Are genetic tests coming
Ulrik Kvist
Karolinska institute, STOCKHOLM, Sweden

IS-071 Are sperm tests vanishing?
Aleksander Giwercman
Malmö University Hospital, MALMÖ, Sweden

IS-072 Cryopreservation of testicular tissue
Claus Yding Andersen1, Erik Ernst1
1University Hospital of Copenhagen, COPENHAGEN, Denmark
2University of Aarhus, AARHUS, Denmark

Gala dinner
### Tuesday June 17th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:45</td>
<td><strong>Plenary: Anatomy of the pelvic floor</strong></td>
<td>Main Hall</td>
</tr>
<tr>
<td></td>
<td><em>Chair: Jens Guðmundsson</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>IS-073 Anatomy of the pelvic floor</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Swift</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Medical University of South Carolina, CHARLESTON, SC, USA</em></td>
<td></td>
</tr>
<tr>
<td>09:45–11:00</td>
<td><strong>Pregnancy, delivery and the pelvic floor</strong></td>
<td>Main Hall</td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Steingrímur Björnsson and Sophie Berglund</em></td>
<td></td>
</tr>
<tr>
<td>09:45–10:00</td>
<td><strong>IS-074 Epidemiology of female urinary incontinence and prolapse – the impact of pregnancy and delivery</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guri Rørtveit</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>University of Bergen, BERGEN, Norway</em></td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td><strong>IS-075 Teaching doctors to diagnose and repair perineal lesions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ranee Thakar</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Mayday University Hospital, CROYDON, United Kingdom</em></td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td><strong>IS-076 Teaching midwives to diagnose and repair perineal lesions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sara Fevre Kindberg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Perinatal Epidemiology Research Unit, ÅRHUS N, Danmark</em></td>
<td></td>
</tr>
<tr>
<td>10:30–10:50</td>
<td><strong>IS-077 Obstetrical lesions and the importance of quality of primary repair</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdul Sultan</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Mayday University Hospital, LONDON, United Kingdom</em></td>
<td></td>
</tr>
<tr>
<td>10:50–11:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:45–11:00</td>
<td><strong>Pediatric and adolescent gynecology</strong></td>
<td>Hall 1</td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Laure Morin-Papunen and Ebba Margrét Magnúsdóttir</em></td>
<td></td>
</tr>
<tr>
<td>09:45–10:05</td>
<td><strong>IS-078 Gynecological examination of children and adolescents</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minna Joki-Erkkilä</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Tampere University Hospital, TAMPERE, Finland</em></td>
<td></td>
</tr>
<tr>
<td>10:05–10:20</td>
<td><strong>IS-079 Chlamydia infection – a worry for the young women or for the gynecologist?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Finn Egil Skjeldestad</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Institute of laboratory medicine, children- and womens’ diseases, TRONDHEIM, Norway</em></td>
<td></td>
</tr>
<tr>
<td>10:20–10:35</td>
<td><strong>IS-080 Trends in adolescent abortion and pregnancy rates in the Nordic countries</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dan Apter</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Väestöliitto, HELSINKI, Finland</em></td>
<td></td>
</tr>
<tr>
<td>10:35–10:50</td>
<td><strong>IS-081 A model for providing contraception and other services for adolescents</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lena Marions</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Karolinska Institutet, STOCKHOLM, Sverige</em></td>
<td></td>
</tr>
<tr>
<td>10:50–11:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:45–11:00</td>
<td><strong>Premenstrual syndrome/Premenstrual dysphoric disorder</strong></td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td><em>Chair: Olle Eriksson and Arnar Hauksson</em></td>
<td></td>
</tr>
<tr>
<td>09:45–10:15</td>
<td><strong>IS-082 Etiology and pathogenesis of PMDD/PMS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Torbjörn Bäckström</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Umeå University Hospital, UMEÅ, Sweden</em></td>
<td></td>
</tr>
<tr>
<td>10:15–10:45</td>
<td><strong>IS-083 Treatment of premenstrual dysphoric disorder</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inger Sundström Poromaa</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Uppsala University, UPPSALA, Sweden</em></td>
<td></td>
</tr>
<tr>
<td>10:45–11:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
09:45–10:55 Obstetrics – focus on the fetus. Free communications VI

Chairs: Oskari Heikinheimo and Anna-Karin Wikström

09:45–09:55 OF1 Antenatal corticosteroids in preterm infants
Lena Eriksson¹, Bengt Haglund², Helle Kieler¹, Viveca Odland¹
¹Medical Products Agency, UPPSALA, Sweden
²Socialstyrelsen, STOCKHOLM, Sweden
³Karolinska Institutet, STOCKHOLM, Sweden

09:55–10:05 OF2 Placenta previa – a risk factor for small for gestational age babies. A Danish population based study
Lone Nikolide Nørregaard¹, Steen Rasmussen¹, Thomas Bergholt¹
¹Hillerød Sygehus, HILLERØD, Denmark
²National Board of Health, COPENHAGEN, Denmark

10:05–10:15 OF3 Systolic myocardial velocity alterations in the growth retarded fetus
Lene Unnack Larsen, Olav Bjørn Petersen, Keld Sørensen, Erik Sloth, Niels Uldbjerg
Aarhus University Hospital Skejby, AARHUS N, Denmark

10:15–10:25 OF4 Modifiable determinants of fetal macrosomia. Role of life style related factors
Nanna Voldner¹, Kathrine Froslie¹, Kari Bo², Lene Haakstad², Camilla Hoff¹, Kristin Godang¹, Jens Bollerslev¹, Tore Henriksen¹
¹Rikshospitalet Medical Centre, OSLO, Norway
²Norwegian School of Sport Science, OSLO, Norway

10:25–10:35 OF5 Perinatal outcome of children born to mothers with thyroid dysfunction. A prospective population-based cohort study
Tuija Männistö¹, Marja Vääräsmäki¹, Anneli Pouta¹, Anna-Liisa Hartikainen¹, Aimo Ruokonen¹, Heljä-Marja Surcel¹, Aini Bloigu¹, Marjo-Riitta Järvelin¹, Eila Suvanto-Luukkonen¹
¹University of Oulu, OULU, Finland
²Dept Obstetrics and Gynecology, University of Oulu, OULU, Finland
³National Public Health Institute, OULU, Finland
⁴Dept Clinical Chemistry, University of Oulu, OULU, Finland
⁵Dept Epidemiology and Public Health, Imperial College, LONDON, United Kingdom

10:35–10:45 OF6 Danish national controlled cohort study on neonatal outcome of 1267 children born after transfer of cryopreserved IVF and ICSI embryos in 1995 to 2006
Anja Pinborg¹, Anne Loft¹, Steen Rasmussen¹, Anders Nyboe Andersen¹
¹Rigshospitalet, COPENHAGEN, Denmark
²Danish National Board of Health, COPENHAGEN, Denmark

10:45–10:55 OF7 No correlation between rates of caesarean section and perinatal mortality
Guðný Jónsdóttir¹, Ragnheiður Bjarnadóttir¹, Alexander Smárason², Reynir Geirsson²
¹University Hospital of Iceland, REYKJAVIK, Iceland
²University hospital of Iceland, REYKJAVIK, Iceland
³Institution of Health, Science and Research, University of Akureyri, AKUREYRI, Iceland

11:00–11:30 Coffee Break / Exhibition

11:30–13:00 New technologies in pelvic surgery – what is the evidence?
Main Hall

Chairs: Søren Broström and Kristín Jónsdóttir

11:30–11:50 IS-084 What is the best sling for stress urinary incontinence
Antti Valpas
South-Karelian Central Hospital, LAPPEENRANTA, Finland

11:50–12:10 IS-085 The use of implants in surgery for pelvic organ prolapse – evidence or marketing?
Daniel Altman
Karolinska Institute, Sweden

12:10–12:30 IS-086 Emerging complications with novel technologies in pelvic surgery
Eckhard Petri
Helios-Clinics, SCHWERIN, Germany
12:30–12:50 **IS-087 Scientific, ethical and legal implications of introducing new technologies in pelvic surgery**
Gunnar Lose
Glostrup County Hospital, GLOSTRUP, Denmark

12:50–13:00 Discussion

11:30–12:55 **Polycystic ovarian syndrome**
Hall 1

Chairs: Per-Olof Janson and Anette Tønnes Pedersen

11:30–11:40 **IS-088 Introduction**
Jens A. Guðmundsson
University Hospital of Iceland, REYKJAVIK, Iceland

11:40–12:05 **IS-089 'In utero veritas' – Fetal intrauterine androgen exposure and PCOS**
Sven M. Carlsen
Institute of Laboratory Medicine, Children’s and Women’s Health, TRONDHEIM, Norway

12:05–12:30 **IS-090 The fertility aspects of PCOS**
Laure Morin-Papunen
University of Oulu, OULU, Finland

12:30–12:55 **IS-091 When pregnant, then what?**
Eszter Vanky
Inst of laboratory medicine, childrens and womens health, TRONDHEIM, Norway

11:30–13:00 **Postterm pregnancies**
Hall 2

Chairs: Thomas Bergholt and Leea Keski-Nisula

11:30–11:50 **IS-092 Induction of post term pregnancy – time to reconsider?**
Ole Jakob Nakling
Sykehuset Innlandet Lillehammer, LILLEHAMMER, Norway

11:50–12:10 **IS-093 Routine induction of labour at 41 weeks gestation: Nonsensus Consensus**
Kåre Augensen
Haukeland University Hospital, BERGEN, Norway

12:10–12:30 **IS-094 Management of post-date pregnancy: Todays’ evidence**
Ulla-Britt Wennerholm
Dep Ob Gyn, GÖTEBORG, Sweden

12:30–12:50 **IS-095 Induction of labour or serial antenatal fetal monitoring in post-term pregnancy. A randomised controlled trial**
Runa Heimstad
St.Olavs Hospital, University Hospital, Trondheim, TRONDHEIM, Norway

12:50–13:00 Discussion

11:30–13:00 **Gynecology. Free communications VII**
Hall 3

Chairs: Jóhannes Guðmundsson and NN

Louise Thunell, Elsa Ryde-Blomqvist, Viveca Odling, Ian Milsom
1Department of Obstetrics and Gynecology, Malmö University Hospital, MALMÖ, Sweden
2The County Council’s Mutual Insurance Company (LOF), STOCKHOLM, Sweden
3The Medical Products Agency, UPPSALA, Sweden
4The Department of Obstetrics and Gynecology, Sahlgrenska Academy, GOTHENBURG, Sweden

11:40–11:50 **GY2 Vaginal misoprostol vs placebo before hysteroscopy**
Kevin Oppegaard
Helse Finnmark, HAMMERFEST, Norway
GY3 Factors associated with endometrial polyps in a Danish population
Eva Dreisler, Søren Stampe Sørensen, Gunnar Lose
Glostrup Hospital, University of Copenhagen, GLOSTRUP, Denmark

GY4 To avoid adhesion occlusion – Ethicon Intercoat is the solution
Per Lendorff
Region Hospital Viborg, VIBORG, Denmark

GY5 The treatment of a tub-ovarian abscesses is usually antibiotics and surgery: What about ultrasound guided drainage?
Seth Granberg¹, Erling Ekerhovd, MD., Ph.D.,² Knut Gjelland, MD³
¹Dept OB GYN, Karolinska Univ. Hospital, Kvinnoklinikken, Akershus Univ. Sjukhus, STOCKHOLM, Sweden
²Dept of Obstet and Gynecol, Sahlgrenska University Hospital, GOTHENBURG, Sweden
³Dept. of Obstet. and Gynecol., Bergen University, BERGEN, Norway

GY6 A Danish National survey on subjective cure, satisfaction and complications 4 years after Tension free Vaginal Tape (TVT)
Astrid Ammendrup, Pia Sander, Gunnar Lose
Glostrup Hospital, GLOSTRUP, Denmark

GY7 Tension-free Vaginal Tape (TVT) versus Tension-free Vaginal Tape-Obturator (TVT-O) – one year follow-up results of Randomized Clinical Trial
Antti Valpas¹, Pauliina Aukee², Aarre Kivelä³, Eija Laurikainen⁴, Kirsi Rinne⁵, Teuvo Takala⁶, Carl-Gustaf Nilsson⁷
¹South-Karelian Central Hospital, LAPPEENRANTA, Finland
²Central-Finland Central Hospital, JYVÄSKYLÄ, Finland
³Oulu University Hospital, OULU, Finland
⁴Turku University Hospital, TURKU, Finland
⁵Kuopio University Hospital, KUOPIO, Finland
⁶Päijät-Häme Central Hospital, LAHTI, Finland
⁷Helsinki University Central Hospital, HELSINKI, Finland

13:00 Closing ceremony. Prizes awarded for best presentations
Main Hall
Refreshments